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1. INTRODUCTION 
 Siddha system of medicine is a peculiar science and it is an uncomparable 
system of medicine.  It is a medical science comprising with it all kinds of science’s 
as alchemy, philosophy yoga, astrology etc. 
 The siddha system of medicine is peculiar only to the tamil country as all the 
siddhars are tamilians except some as Bogar.  It is a science clearly attributed to the 
grace of God Shiva and Parvathi.  Siddha system was founded many thousands of 
years age and the intellectual activity in all its arts and sciences in real of medicine it 
was indeed a golden age. 
 Siddha treatment given for curing disease according to the methods laid down 
in the medical works of siddhars.  According to them disease consists of two classes, 
physical and mental, which reder to deviation from the normal physiological of 
psychological condition, respectively and these two have a common constitutional 
back ground and so neither is known to exist without the other moreover, the siddha 
treatment consists not merely with the external body of the man but also the inner 
man or the soul.  It is based more on spiritual basis than on materialistic one the 
siddhars have written from their spiritual knowledge and experience and therefore the 
tenth of them cannot be derived by any one or criticized. 
 The term “Siddhar” has derived from the word “Siddhi” which literally means 
accomplished achieved or perfected success and so it readers to one who had attained 
his end is spiritual goal. 
 “sqf<jkbqOz!gtr<glx<xiI!sqk<keiuie<”!
! ! ! ! ! ! ngk<kqbI!GVF~z<!Lh<H,!.61!
“Ns<sh<hi!kk<Kuk<jk!B{i<f<Okie<!sqk<ke<” 
 “Siddha Siddhi” means firmness of mind success in gleaning the control of the 
mind. Siddha also refus to a seer, saint, or semidevine being supposed to posses 
super natural powers of which only eight are enumera to (astama siddhi) they were the 
greated scientists in ancient times. 
 Importance of body said by saint Thirumoolar is, 
 “dml<hiI!npqbqe<!dbqviI!npqui<!
! kqml<hm!olb<Riel<!OsvUl<!lim<miI!
! dml<jh!uti<g<Gl<!dhibl<!nxqf<Ok!
! dml<jh!uti<k<Oke<!dbqi<uti<k<OkOe”!
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  According to Siva vakiyar removing negativity mind always gives inner 
strength to overcome Narai, thirai, moopu, pini as 
 “lek<kgk<K!nPg<gxik!lUeRie!Obigqgit<!
! uek<kgk<K!-Vg<gqEl<!lek<kgk<K!nPg<gxiI!
! lek<kgk<K!nPg<gXk<k!lUeRie!Obigqgit<!
! Ljzk<kmk<K!-Vg<gqEl<!hqxh<hXk<K!-Vh<hOv”!
   According to valluvar when the mind is pure the ill effects of body will not 
happen, it gives only good effects as 
“lefzl<!le<EbqI!gig<Gl<” 
 In our peadiatric OP Many skin patients are attending.  Among them the so 
called karappan cases are vulnerably affecting among the peadiatric community.  So 
the author tempeted to know detailed about this karappan Noi and willing to create 
some awareness to eradicate the karappan and to educate the management.  Those 
who are affected by this disease. 
 In many peadiatric siddha literatures widely described the management with 
the drugs for many disorders among them the authour find out a fine drug karappan 
kudineer choornam (Internally)  and karappan Ennai (Externally) to evaluate the 
clinical efficacy of these drugs aiming towards the treatment of Sattai karappan. 
 The Sattai karappan disease signs and symptoms very well corealated with 
atopic dermatitis.  The detailed about the AD is well described in the modern 
peadiatric text books, that the same have been refered and also given in the modern  
literatures review.  
! The peadiatric medicines are widely described almost all siddha text and 
among the common disease like karappan and its treatment also noted by the siddhars 
in this text book.  So, author was mostly interested to collect the knowledge about 
karappan in children and its management have been noted in this dissertation. 
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2. AIM AND OBJECTIVE 
AIMS 
 Sattai karappan is a major health hazard in the developing countries like India.  
It is the commonest skin problem among children.  It affects children in their active 
period of life and cause severe embrassment both physically and mentally. 
 Sattai karappan is highly adhered by polluted environments, allergic food 
edibles and lack of hygiene which are the main causative factors for developing this 
disease.  So that when the disease has once occurred remission and relapse happens 
subsequently throughout the life. 
 
Objectives 
 To bring out the treatment for sattai karappan a long standing malady of 
human. 
 To collect and review the ideas mentioned in siddha literatures about sattai 
karappan. 
 To collect ideas about sattai karappan with observation of the etiology, clinical 
features, diagnosis, prognosis, complications based on modern aspects. 
 To have an idea about the incidence of sattai karappan with reference to age, 
sex, socio economic status, habits, occupation, family history and 
paruvakalangal. 
 To expose the siddha diagnostic methods for diagnosing the disease. 
 To know how the sattai karappan alters uyirthathukkal and udalthathukkal 
 To evaluate the biochemical  analysis and pharmacological study of Karappan 
kudineer chooranam (Internally), Karappan ennai (Externally)and observe the 
efficacy of the medicine clinically. 
 To study the progress of the patients with the help of modern diagnosis 
parameters. 
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3. REVIEW OF SIDDHA LITERATURE 
SIDDHA ASPECT 
sm<jm!gvh<hie<< < << < << < <!
Le<Ejv<<< !
! leqkeqe<! dml<H! hz<OuX!dXh<Hgtiz<! gm<mjlg<gh<hm<m! yV! nkqsb!
%XhiMjmbK/! njugt<! njek<Kl<! hR<sH,kr<gtqe<! %m<Mxuiz<!
dVuig<gh<hm<mK/! !njugTt<! l{<! )n*! hqVkquq! H,kk<kqe<!%Xhimig! lbqi<?!
Okiz<?!we<H?!-jxs<sq?!fvl<H!Ngqbjugt<!njlf<K!gi{h<hMgqxK/!!-jkOb!
skg!fic!
! “Osvh<hi!smlis<S!l{<{qe<!%X!
! osxqlbqx<!Okiz<!we<hqjxs<sq!fvl<jhf<kiGl<! ! ! !
. skgfic!
!! we<X! -bl<HgqxK/! ! Olx<g<gi[l<! nu<juf<K! dXh<HgtqEl<! Okiz<?!
dml<hqe<! lqgh<ohiqb! dXh<hiGl</! ! OlZl<! lqg! fQ{<mkie! njlh<Hl<!
djmbkiGl</! ! OlZl<! dml<hqe<! dt<! dXh<H! njek<jkBl<! OhiIjuOhiz<!
OhiIk<kq?! sgz! dXh<HgjtBl<! hiKgig<Gl</! ! lqgh<ohiqb! hr<jg! ugqg<gqxK/!!
weOu! nk<kjgb! ohVjl! lqGf<k! Okiz<! wf<OfiBl<! n[giK! hiKgih<hK!
gmjlbiGl</! ! Neiz<! WOki! sqx<sqz! ng?! Hx! giv{r<gtqeiz<! sqz!
Oujtgtqz<! Okiz<! lqGkqBl<! hikqh<Hg<Gt<tigqxK/! ! nu<uiX! Okiz<! hikqk<K!
wPl<! Ofib<gtqz<! ye<X! gvh<hie<! NGl</! ! gjvkz<! we<hK! gvh<hie<! Ofibqz<!
OkizieK! npqf<K?! hqiqf<K?! gjvf<K! ke<eqjzbqz<! -Vf<K! OuXhm<M!
gi{hMukiz<!-u<uiX!njpg<gh<hMgqxK/!
! gvh<hie<! we<hK! Ngik! gix<X! )n*! liXhm<m! ohiVm<gtqe<! l{l<!
Ngqbjugjt! LgVl<! ohiPOki! )n*! Ngik! ohiVm<gt<! dml<hqe<! Olz<!
hMgqe<x! ohiPOki?! dml<hqe<! dm<hGkqbqz<! Wx<hMl<! sqz! Oukquqje!
lix<xr<gtqeiz<! uvg<%cb! wkqi<uqjtUgt<! Okizqz<! hqvkqhzqg<Gl<! ke<jl!
outqh<hMkz<!we<X!ohiVt<hMl<hc!njpg<gh<hMgqxK/!
! gvh<hie<!we<hK!hkqoem<M!ujgbie!gvh<hie<gtqz<!ye<xiGl</!gjvh<hie<!
Gpf<jkgTg<G!d{<miGl<!hq{q!NGl</!!hizuigml<!F~zqz<!uqtg<gh<hm<Mt<t!
GxqG{r<gtqe<! nch<hjmbqz<! Ofibqjeg<! g{qk<K?! sqk<k! lVk<Ku! Ljxk<!
Oki<Ugtie! Lg<Gx<x! OuXhiMgt<! WPujg! dmx<kiKg<gt<! Gx<xr<gtqe<!
ke<eqjz!uti<s<sq?!Oux<Xfqjz!uti<s<sq?!hq{qbxqLjxjl?!w{<ujgk<Oki<Ugt<!
nch<hjmbqz<! Ofibqje!Nvib<f<K!nkx<gie!hq{qfQg<g!LjxBl<?! Ofib<uvilz<!
kMg<Gl<!upqgTl<!-kqz<!uqtg<gh<hm<Mt<te/!
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! gvh<hie<!we<hK!gxk<kz<!we<x!ohiVm<hMgqxK!Woeeqz<!OkizieK?!ke<!
-bx<jg!fqxl<!lixq!gXk<K?!uqMukiz<!-u<uiX!%xh<hMgqxK/!
gvh<hieqe<!-bz<< < << < << < <!
! gvh<hieqe<!-bz<!we<X!Ofig<Gl<!OhiK?!hz<OuX!sqk<k!lVk<Ku!F~x<gt<!
sqx<sqz!OuXhiMgTme<!ohVhie<jlBl<!ye<xigOu!djvg<gqe<xe/!!njugTt<!
Gpf<jkgTg<Gl<?! ohiqObiIgTg<Gl<! uVl<! ke<jlgTl<! yOv! uqkligOu!
wMk<kqbl<Hgqe<xe/!!Neiz<?!-r<G!gvh<hie<!hx<xqb!-bzig!Gpf<jk!lVk<Kul<!
wEl<!F~zqz<!gQp<gi[liX!%xh<hm<Mt<tK/!
• dmzqz<!kqlqi<?!kqeU?!osixq?!H{<?!kch<H?!ouch<H?!fQIg<gsqkz<!Ngqb!
GxqG{r<gjt!d{<mig<Gl<!!
• dml<hqe<!-bx<jg!fqxk<jk!OuXhMk<Kl<!
Nkivl<;!Gpf<jklVk<Kul<?!!
Nsqiqbi<;g/s/LVOgsLkzqbiI?!
lV/ohie</GVsqOvie<l{q/!
OlZl<!sqk<k!lVk<Kul<!sqxh<H!wEl<!F~zqz<< < < < < < << < < < < < << < < < < < <!
• Okizqz<! kqlqI?! GV?! H{<?! kch<H! Ngqb! GxqG{r<gjt! djmb!
hjmgjt!d{<mig<Gl</!
• nu<uqmr<gtqz<!uQg<gl<?!ogih<Htr<gt<!g{<M!nz<zK!oskqz<!Ohie<X!
Okiz<!SvSvh<higq!Okizqe<!-bx<jg!fqxk<jk!OuXhMk<kqg<!gim<Ml</!
• sqzOujt! ouch<H{<mig<gq?! fQIg<gsqkz<! Ngqb! GxqG{r<gjt!
gim<Ml</!
• -kqz<!kqeUl<?!osixqBl<!-Vk<kZl<!-z<zikqVk<kZl<!d{<M/!
-kje!OlZl<!Ovig!fqi<{b!sivl<!we<El<!F~zqz<< < < < < << < < < < << < < < < <!
• Okgk<kqz<! wiqs<sz<?! fjls<sz<?! njvh<H?! kch<H! gi[l<! we<X!
%xh<hm<Mt<tK/!
OlZl<!hqt<jth<hq{q!lVk<Kul<!< < < < << < < < << < < < < .!3bqz<<<<!
• dmz<! LPuKl<! H{<?! kch<H! -v{k<jk! d{<mig<gq! ogih<Htr<gt<!
g{<Ml<!
• Okizqe<! -bx<jg! fqxk<jk! OuXhMk<kq! sqzOujt! ouch<H?!
fQIg<gsqkjz!d{<mig<Gl</!
• uxm<sqjb!Wx<hMk<Kl<!
• Okijzh<!hx<xqb!-v{!Ofib<!we!-ke<!-bz<!uqtg<gh<hMgqxK/!
-kje!okimi<f<K!hvvisOsgvl<!hizOvig!fqkiek<kqz<?< < < < << < < < << < < < < !
• gvh<hie<! we<hK! ljxf<K! hqe<ei<! outqh<hMkz<?! gvh<hie<! we<hK!
Okizqe<!fqxk<jk!gVjl!fqxljmb!osb<ukiz<!giqh<hie<!weUl<?!
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• gvh<hie<! we<hK! Okijz! gjvg<Gl<! ke<jl! djmbkiz<! gjvh<hie<!
we<Xl<!osiz<zh<hMgqxK/!
Ofib<!uVl<!hVul<< < << < << < <!
! kiz! hVul<! Lkz<! uVjg! hVul<! ujvBt<t! fie<G! hVur<gtqZl<!
gvh<hie<!Ofib<!Gpf<jkgTg<G!d{<miGl</!
! “kbr<G!g{f<!Okie<Xf<!kie<!gvh<hie<!.!fbl<hmOu!
! uf<K~Xl<!ng<g{k<kqz<!uikg<!gvh<hie</!
gvh<hie<!Ofib<g<gie!giv{r<gt<< < < < < << < < < < << < < < < <!
! “hqxf<kfit<!hqt<jtg<Gk<!kiOe!fe<xib<!
! ! hqkiuiOz!hq{qBmzqe<!OlOz!Okie<Xl<!
! sqxf<khq{q!g{lif<kl<!gvh<hie<!Okiml<!
! ! kQkiV!lg<gvr<gt<!gqvf<kq!Le<eil<!
! nxf<kjpg<G!lVf<kxqjR!bieix<!xQVl<!
! ! nKue<xq!lVf<kxqR!eieix<!xQVl<!
! kqxf<okxqf<K!hiIk<KuqM!sqXhqt<jtg<Gs<!
! ! sQvig!uV!Ofib<gt<!osh<hg<OgOt!
! ! ! ! Nkivl<;!hizuigml<!hg<gl<;!7!
!! gVuqzqVg<Gl<! sqS! kibqe<! ubqx<xqzqVf<K! outquf<kUmOeOb/!
outqs<$p<fqjz!giv{r<gtiz<!Ofib<!Wx<hMuKlm<Mle<xq?!nke<!ohx<OxiIgtqe<!
dmz<fqjz! giv{ligUl<! Ofib<! Wx<hMl</! ! -KOhie<X!d{<miGl<! Ofib<gtqz<!
gvh<hiEl<!ye<xiGl</!
! “Gm<mlK!uqm!gvh<hie!uqmfQI!$jz!
! ! SOvi{qkk<kiz<!kiKogm<Mk<!kch<H{<miGl<!
! lm<mxOl!gqVlqose<X!lVUl<OhiK!
! ! ujgbib<g<!gqVlqBm!uqmfQI!ose<X!
! Gm<mLme<!Okgolz<zil<!hxg<Gl<OhiK!
! ! GpqGpqbib<g<!gqVlqbqeQIg<!ogit<Tl<!Ht<tq!
! km<mxOu!gqVlqBm!fQviz<!uf<k!
! ! sgzGm<ml<!uqm!gvh<hie<!six<x!ziOl”!
! ! Nkivl<;!Ofib<!fimz<!Ofib<Lkz<fimz<!higl<!.2?!hg<gl<;!468!
uqmgvh<hie<! uqmfQI! $jz?! Sg<gqz! fm<ml<! -ux<xiz<! kiKg<gt<! ogm<M!
kch<H{<miGl</! ! -kqz<! gqVlqB{<mib<?! gqVlqBm! uq]fQI! Okgolz<zil<! hvuq!
GpqGpqbib<! Ht<tq! Ht<tqbib<g<! gqVlqBm! uqm! fQviz<! Gm<ml<?! uqmgvh<hie<!
dx<hk<kqbiGl<!we<xxqbzil</!
! !
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B,gq!juk<kqb!sqf<kil{qbqz<< < << < << < <!
! “Wpie!gvh<hieqe<!dx<hk<kqg<!Ogtib<!
! ! Wx<xlib<!lilqsr<gt<!Hsqg<jgbiZl<!
! %pie!gl<H!kqje!uvG!sijlg<!
! ! ogickie!gqpr<G!ujgbVf<k!ziZl<”!
lilqsr<gt<?!gl<H?!kqje?!uvG?!sijl?!gqpr<G!-ux<jx!Hsqh<hkiz<!Gpf<jkg<G!
gvh<hie<!Ofib<!d{<migqxK/!
hvvis!Osgvk<kqz<< << << <!
! “Ougg<!gix<xk<kqei<!hjeouz<zk<kiz<!
! ! higlqg<gzie<!Olkqh<!hioubqziz<!
! kigliqe!uVg<g!kqsif<kziz<!
! ! Olig!uijp!uPkjz!Lt<tqg<git<!
! giBl<!hz<zmk<!kix<Svk<!kix<gtqz<!
! ! wBl<!u{<omzq!biz<!uVOl!Koutq!
! Gc!fz<zxquie!wVuqeiI!
! ! bielie!gvh<hie<!ujggOt!
• nkqgh<hcbie!hjeouz<zl<?!uijp?!gk<kiqg<gib<!d{<[kz<!
• gix<X!upqbig!okix<x!%cbkigUl<!
• hz!uq]g<!gcbqeiZl<!d{<miGl</!
ujggt<<<<!
Ng!gvh<hie<!ujggjt!%Xl<!wf<k!F~Zl<!sm<jm!gvh<hie<< < << < << < <!wEl<!yV!
ujgjb!%XgqxK/!!nkeqe<Xl<!sm<jmgvh<hieqe<!Lg<gqbk<Kuk<Kul<!-r<G!
Nvibh<hMgqxK/!
B,gq!juk<kqb!sqf<kil{q!F~zqz<!8!ujggtig!%xh<hMgqxK< < < << < < << < < < !
! “Nole<x!gvh<hie<kie<!WPuqk!liGl<!
! ! nmr<giK!kek<kqe<!gvh<hiOeiM!
! giole<x!g{ib<!gvh<hieiGl<!
! ! gMgqbOkiI!uxm<sqbir<!gvh<hiOeiM!
! Okole<x!kqlqi<uikg<!gvh<hie<!fiEl<!
! ! sqvsqeqOz!obPghizg<!gvh<hie<!kiEl<!
! Ohoee<x!hqk<k!lir<!gvh<hiOeiM!
! ! ohiqbOsm<!Mlg<gvh<hie<!ohbi<ki!Oep” 
2/ uikgvh<hie<!
3/ hqk<k!gvh<hie<!
4/ gh!gvh<hie<!
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5/ g{<m!gvh<hie<!
6/ uxm<sq!gvh<hie<!
7/ ghiz!gvh<hie<!
8/ kqlqi<uik!gvh<hie<!
Ofib<!ohiK!GxqG{r<gt<< < << < << < <!
 “w{<hK!gvh<hie<!ke<je!bqbl<hqMliX!OgtQI!
! ! e{<hqMl<!uikl<!hqk<kl<!fzr<ogm<Mk<!kiel<!uQr<Gl<!
! H{<hMl<!gvr<gt<!sf<kq!H{zf<Kmz<!gMk<K!OfiGl<!
! ! ue<Hme<!ouck<Ks<!$jz!uVuK!v{!lQoke<Oei<!
. ngk<kqbi<!-v{F~z<!
“djpR<S!OlzbqXk!we<!sQkr<gi[l<!d]<{lib<!&k<kqvf<kiZVf<kq!uqPl<!
njpR<SOlbr<golz<ziR<!osiiqB{<miGl<!npzig!ouKl<hzib<g<!jggiOziBl<!
HjpR<SOlzqr<gk<kqx<!He<Ohiz<Vk<kh<!!ohich<ohicbib<!S{<{il<Hg<!gz<Ohiz<!uqMl<!
goeR<SOl!fQOviM!lzLR<sqg<Gl<!gsqBOl!gvh<hieil<”!
• dmz<!LPuKl<!kch<H!
• gQz<gtqz<!uzq!
• kch<Hme<!niqh<H!dmz<!LPuKl<!gi{h<hmz<!
• Gpf<jkbqeK!dml<ohz<zil<!hiz<!OgiIk<Kg<!ogi{<m!osixq!Ohiz<!
Wx<hMl</!
• dml<ohz<zil<!H{<!Wx<hm<M!GVkq!ucBl</!
• gcuqmr<gtqz<!kch<H!Ohiz<!gi[l</!
• nkqz<!fqe<Xl<!heqk<Ktq!Ohiz<!fQIhib<f<Kl<!ux<xqBl<!fiXl</!
• gQz<gt<?!gPk<K!-u<uqmr<gtqz<!ouck<K!H{<{iGl</!
• jggiz<?!okijm!-Mg<Ggtqz<!-u<uqmr<gtqz<!uzq!d{<mig<gq!hqe<!
dmz<!LPuKl<!hvuq!kck<kz</!
Lx<GxqG{l<< << << <!
• dmzqe<!Okizqz<!fjls<sz<!Wx<hm<M!osixqBl<?!hqe<!osixqf<k!-mk<kqz<!
sqxqK!ngzk<Kg<Gk<!kch<H!Wx<hm<M!Oui<g<GV!Ohiz!d{<migq!lQ{<Ml<!
kqeouMg<Gl</!
• ogih<Htr<gt<!ouck<Kh<!H{<{igq!wiqs<sz<?!fQIg<gsqU!Wx<hMl</!
• kch<H!fiTg<G!fit<!kti<f<K!ogi{<Om!uVl</!!nkqz<!gsqBl<!fQIhm<m!
-molz<zil<!-K!Ohie<Ox!osixqH{<migq!kch<Hl<!d{<miGl</!
• Lx<xqb!fqjzbqz<!kujtbqe<!Okiz<!Ohiz<!gi{h<hMl</!!Okizqe<!fqxLl<!
lix<xljmBl</!
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• sqzujg!gvh<hieqz<!fQI!ucbilz<!uxm<sqbig!-Vg<Gl</!!sqzux<xqz<!
DeQve<xq!GVkqBl<!gsqbzil</!!gsqf<k!DeQI!djxf<K!
hg<Ggm<MkZl<?!Hziz<!fix<xl<!uQSkZl<!d{<M/!
sm<jm!gvh<hie<< < << < << < <!GxqG{r<gt<< << << <!
lr<jg!gQzqz<!uzq!gt<tqh<!H,oue!lzi<f<K!uiiqbqM!olb<bqeqx<!
ohir<G!fQIheqgt<!Ohiz<uqPf<Kmzl<!ouh<h!ligqzr<sqg<gqOb!
Kr<!liesqv!OfiUligq!uti<f<K~b!ue<elqK!KOumlil<!
kr<G!sm<jmgvh<!hioees<!sqgqs<js!kiOe!kx<Guiqk<OkiKuil<!
• gQz<gtqz<!uzqk<kz<!
• hqxG!gt<tqh<!H,juh<Ohiz<!dml<ohz<zil<!gqjtk<kz<!
• heqk<KtqOhiz<!fQI!gsqkz<!
• dmz<!ouh<hlibqVk<kz<!
• lzR<sqg<Gkz<!
• kjzOfikz<!
• Osix<xqz<!ouXh<H!
Nkivl<!Gpf<jk!lVk<Kul<!Nsqiqbi<!
gi/s/!LVOgs!Lkzqbii<?!lV/!
ohie<GVsqOvie<leq!
!
• giz<!gMg<Gl<!
• gQz<gt<?!gPk<K!-u<uqmr<gtqz<!ouck<Kh<!H{<{iGl<!
• giz<?!jg?!!sf<K!Ngqb!uqmr<gtqz<!gcuqmr<gtqz<!kch<Hh<!Ohiz<!!!
gi[l</!
• nkeqe<Xl<!heqfQi<!Ohiz<!fQi<!hib<f<K!ux<xqBl<!fiXl<!
• Gpf<jk!-jtg<Gl<!
• Gpf<jkbqeK!dml<ohz<zil<!hiz<!Ogii<k<Kg<!ogi{<m!osixq!Ohiz<!
Wx<hMl<!
• sijv!hil<hqe<!dmz<!Ohiz!NGl<!
• dml<ohz<zil<!H{<gt<!Wx<hm<M!uq]fQi<!GVkq!Ohie<X!ucBl<!
• dmz<!-jtk<K!npgqpf<K!OhiGl<!!
• dml<H!sg<kq!-pf<K!fMg<gl<!d{<miGl<!
• oki{<jmbqz<!H{<!Wx<hm<M!dmz<!ouh<hliGl<!
Nkivl<;!!hqt<jth<hq{q!lVk<Kul<!.!3!!
hg<gl<!;!!663!
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• giz<?!jg?! !KjmbqMg<G!-u<uqmr<gtqz<!uzqB{<migqh<! hqe<H!dmz<!
LPuKl<!hvuq!kck<kz<!!
• fig<gqz<!H{<!Wx<hmz<!
Nkivl<!;!<<< uqv{!gvh<hie<!svOhf<kqvi<!!
juk<kqb!Ljx!hg<gl<!:!47!
• Okgl<!olzqBl<!
• sf<K!giz<!gMg<Gl<!
• g{<ml<!ouck<Kh<!H{<{igqg<!gcuq]l<!Ohiz<!fQi<!hib<f<K!fiXl<!
)OuX*!
• Okgolz<zil<!hvhvk<Kh<!osiiqOhizigqs<!sjvHmx<!Ohiz<!gi[l<!
• H{<{qz<!uq]szl<!dkqvl<!Ohiz<!ucBl<!
• Gjzux<xqk<!kQVl<!
Nkivl<;!<<< Nk<lvm<silqi<kole<El<!juk<kqb!!
sivsr<gqvgl<!hg<gl<!;!217!
• giz<?!jg?!okijm!-Mg<G!Lkzqb!-mr<gqz<!uzq!d{<miGl<!
• uq]g<gcjbh<!Ohiz<!dml<H!LPuKl<!hvuzig!kcg<Gl<!
• nju!H{<gtig!liXl<!
• fig<G?!oki{<jm!Lkzqb!-mr<gtqZl<!H{<gt<!d{<miGl</!
• gib<s<sz<!d{<miGl<!
Nkivl<!;!!<<< Gpf<jk!juk<kqbl<!lVf<Kl<!!
lif<kqiqgLl<!hg<gl<!;!223!
• g{<ml<!ouck<K!-Vg<Gl<!
• gcuq]l<!Ohiz<!fQi<gsqBl<!
Nkivl<!;!!<<< Ovig!fqi<{b!sivl<!we<El<!!
Ovig!fqkiel<!hg<gl<!;8!
“giz<gvl<!-Mh<H!sf<K!g{<mLl<!oucg<Gl<!H{<[l<< < < < < < < < < << < < < < < < < < << < < < < < < < < <!
! Olz<!Wuqsl<!)< << << < @*!Ohizg<!gm<cuqiqf<K!he<eQOv!< < < < Q< < < < Q< < < < Q [hiBl<!<<< !
OgizOl!ouKl<hq!fiZl<!GpuqBOliMr<!GlvOu< < << < << < < !
! liOzEr<!Gpzib<!Ogtib<!uijzbir<!< < < << < < << < < < [gvh<h)i*!EOl<<< ”!
• giz<?! jg?! -Mh<H?! gQz<?! gPk<K! Ngqb! -mr<gtqz<! ouck<Kh<!
H{<{iGl</!
• nkqz<!-Vf<K!he<eQi<!Ohiz<!fQi<!hiBl<!
• Gpf<jk!ouKl<hq!gi[l</!
Nkivl<;!<<< hqt<jth<hq{q!uigml<!hg<gl<!;!!49 
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-eq!gvh<hie<!Ofib<!uVukx<gie!giv{r<gjt!Nvibzil</< < < < < << < < < < << < < < < < ! !
Lg<Gx<x!OuXhiM< << << < !
! &e<X! kiKg<gt<! Gx<xl<! njmukiZl<! )n*! OuXhiM! njmukiZl<!
hq{qgt<!Wx<hMgqe<xe/!
sm<jmg<gvh<hieqz<!d{<miGl<!Lg<Gx<x!OuXhiMgt</< < < < < < < < << < < < < < < < << < < < < < < < < !
!! sm<jmg<gvh<hieqz<< < < << < < << < < <! d{uikq! osbz<! liXhim<miz<! utqg<Gx<xl<! Lkzqz<!
OgmjmgqxK/!
• uikl<! hk<K! ujgh<hMl<! nux<Xt<! nhiee<?! uqbiee<?! sliee<?!
gqVgve<! Ngqbju! hikqg<gh<hMukiz<?! ne<esivl<! OsvOu{<cb!
-mr<gtqz<!OsIh<hqg<gh<hmilz<!hikqg<gh<hMgqxK/!
• sivl<! hikqg<gh<hMukiz<?! -vR<sgl<! osf<fQjv!nkqgh<hMk<k!Lcbilz<!
osf<fQI!GjxG{l<!d{<migqxK/!
• -keiz<! hqvisgl<! hikqg<gh<hm<M?! Okizqe<! ytq! GjxgqxK! sm<jmg<!< << << <
gvh<hieqe<< << << <! GxqG{r<gtie! gt<tqh<H,juh<Ohiz<! dml<ohz<zil<!
gqjtk<kz<?!nux<xqzqVf<K!heqk<Ktqh<Ohiz<!fQI!gsqkz<!d{<migqxK/!
• uikl<!hikqg<gh<hm<M!gQz<gtqz<!uzqk<kz<!d{<migqxK/!
• hqk<k!Gx<xl<!hikqg<gh<hm<M!Okizqe<!Olz<!heqk<Ktqh<Ohiz<!fQI!gsqkz<?!
nu<uqmk<kqz<!wiqs<sz<!Ohie<x!G{r<gt<!Wx<hMgqxK/!
• Ofibqe<! fim<hm<m! fqjzbqz<! D{<! lx<Xl<! ogiPh<H! hikqg<gh<hm<M?!
dmz<!-jtk<kz<?!gQz<gtqz<!Ofib<?!OsiIU?!Osix<xqz<!ouXh<H?!kjz!
Ofikz<! Ohie<x! GxqG{r<gt<! sm<jmg<! gvh<hie<< < < << < < << < < <! Ofib<gtqz<!
d{<migqe<xe/!
!
w{<ujgk<!Oki<uqe<!g{qh<hqz<< < < < < << < < < < << < < < < <!
!
fqxl<! ! .!! -bx<jg!fqxl<!OuXhm<M!hikqg<gh<hm<m!hGkqgtqz<!gXh<H!!
fqxl<!gi{h<hMgqxK/!
^<hiqsl<! .!! gt<tqh<H,juh<Ohiz<!dml<ohz<zil<!gqjtk<kz<?!!
nux<xqzqVf<K!heqk<KtqOhiz<!fQI!gsqkz<?!osixq?!H{<?!!
kch<H!gi{h<hm<mK/!
lzl<! ! .! nhiee<!hikqh<H!giv{lig!lzs<sqg<gz<!gi{h<hMgqxK/!
&k<kqvl<! .! jug<Ogiz<!fQI!fqxl<!gi{h<hm<mK/!
fic! ! .! ohVl<hiZl<!gvh<hie<!Ofibqz<!Osk<Kl!fic!gi{h<hm!!
Ou{<Ml</!!keq!ficbig!g{qg<g!Lcbik!giv{k<kiz<?!!
okif<k! ficbig! uikghl<?! hqk<kuikl<?! uikhqk<kl<!
gi{h<hm<mK/!
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ofb<g<Gxq! .! Jbl<!uiPlqmr<gtie?!GVkq?!ogiPh<H?!slieuiB!!
hikqg<gh<hMukiz<!ofb<g<Gxq!Lk<okik<K!fqe<X!ghfQvigg<!!
gi{h<hMgqxK/!
fic!
! w{<ujgk<! Oki<Ugtqz<! ficjbh<! hqvkielig! juk<K! Ofib<gjt!
g{qk<kz<! Kxk<k! ficjbh<! hqvkielig! juk<K! Ofib<gjtk<! Kxf<k!
Ljxobeg<!ogit<tz<!nusqbliGl</!
! ficjbg<!ogi{<Om!hq{qjb!g{qg<g!Ou{<Ml<!we<hjk!nxqf<K!
! “Ofib<fic!Ofib<Lkeic!bK!k{qg<Gl<!
! uib<fic!uib<h<hs<!osbz<”!
“hq{qjb!ficbizxqf<K!Dm<M!lVf<Ok!
sqxf<kokeg<!%xqb!uqmk<K”!
“Lh<hq{q!lVuq!LeqUogit<!Gxqh<jhk<!
kh<hi!kxqBf<!ke<jlBl<!uik!
hqk<kjubh<!hqiqjuBljukil<!
Wxq!bqxr<gq!-j{f<Kg<!gzf<K!
lixq!lixquVR<!osbx<jgbix<!hq{q!
Ofi<jl!bxqf<K!fQm<M!lVf<Ok!
sQiqbki!oles<!osh<Hui<!sqk<kOv”!
. Ofib<fimz<! Ofib<Lkeimz<! kqvm<M!!!!!!!!!!!!!!!
higl<.2?!h/w{<!;!381!
gvh<hieqz<!Okie<Xl<!fic< < < << < < << < < < !
ghfic!
! “kieLt<t!Osk<Klf<ki!eqtgqz<!ouh<H!
! ! sblQjt!-Vlz<!lf<kiv!gisl<!
! =eLXR<!se<eq!uqmOkiml<!uqg<gz<!
! ! bqVk<!Ovigl<!gvh<hie<!uqv{Okiml<!
! lijejebQI!$jzkqvt<!uqbikq!uQg<gl<!
! ! uVR<sk<kq!Suisl<!ofR<sjmh<H!K~g<gl<!
! WeLXr<!gilijz!hi{<M!Osijh!
! ! WPSvr<gt<!hzKg<Gl<!uqmL{<miOl”!
. skgfic!
uikk<Kme<!d< << << < ]<{l<!Osi<f<kiz<< < < < << < < < << < < < <!
! “sqxh<hie!uikk<kq!Zm<ceg<!giz<kiOe!
! ! Osi<f<kqMgq!zkqsiv!Ljts<sz<!uiB!
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! djvh<hie!ohiVlOziM!ng<gqeq!lf<kl<!
! ! d{<miGl<!fQIs<!squh<H!hqvOlgr<gt<!
! hqxh<hiM!lkgiq!fQI!gvh<hie<!vk<kl<!
! ! hqvOlgl<!ohVl<hiM!HxfQIg<Ogiju!
nxh<hie!uiB!$jz!Osk<Kl!Ovigl<!
! ! Nehz!hq{qgTOl!uf<kmr<Gf<kiOe”!
. !skgfic!
sm<jmg<!gvh<hieqz<!Okie<Xl<!ficbiue< < < < < << < < < < << < < < < < !
! uikghl<!
uikhqk<kl<!!
hqk<kuikl<!!
Ngqb!okif<k!ficgt<!gi{h<hm<me/!
!
sqk<k!lVk<Ku!nch<hjmbqz<!hiqOsikje< < < << < < << < < < !
uikl<;< << !
u/w{<<<<!
uikk<kqe<!< << << <
ujggt<<<<!
osbz<gt<< << << <!
sm<jmg<!< << << <
gvh<hieqz<!< << << <
d{<miGl<!< << << <
uqgx<hr<gt<< < << < << < <!
2/!
hqviee<!
)dbqi<g<giz<*!
• &s<Suir<gz<?!&s<SuqMkz<?!d{ju!
osiqg<gs<!osb<kz<!
-bz<H!
3/!
nhiee<!
)gQp<Ofig<Gr<giz<*!
• lzszk<jkk<!kt<Tl</!!Nseuijbs<!
SVg<Gl</!ne<esivk<jk!OsvOu{<cb!
-mr<gtqz<!Osi<h<hqg<Gl<!
lzs<sqg<gz<!
4/!
uqbiee<!
)hvUg<giz<*!
• dXh<Hg<gjt!fQm<mUl<!lmg<gUl<!
osb<Bl<?!
• hiqsr<gjtbxqBl<?!
• d{<[l<!d{uqe<!sivk<jk!
nu<uqmr<gtqz<!fqvh<hqk<K!
dmjzg<gig<Gl</!
Okizqz<!kqeU?!
osixq?!
ogih<Htr<gt<?!
fQIgsqkz<!
d{<mikz</!
5/!
dkiee<!)Olz<!
Ofig<Gr<giz<*!
• dkvig<gqeqbqz<!-Vf<K!Okie<xq!
d{uqe<!sivk<OkiM!!
%cbqVf<K!njk!nr<OgOb!fqXk<Kl<?!
njk!outqh<hMk<kqBl<!gzg<gqBl<!
uVkz<!osb<Bl<!
-bz<H!
6/!
sliee<!
)fMg<giz<*!
• fihqbqzqVf<K!giz<ujvg<Gl<!sleib<h<!
hvuqh<hib<f<K?!lx<x!uiBg<gjt!lqR<s!
lx<x!
uiBg<gijt!
siqh<hMk<Kukqz<!
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ouim<milz<!lmg<gqs<!siqh<hMk<kqs<!
Osvh<h{<[l</!
• nXSjugjtBl<?!ne<el<?!k{<{QI!
Ngqbux<jxBl<!slh<hMk<kq!
dmzqotz<zil<!OsVl<hc!osb<Bl</!
hikqh<H!
7/! fige<!
• nxqju!wPh<Hl<!
• fz<z!h{<Hgjth<!hiMuqg<Gl<!
• g{<gjt!kqxg<Gl<hc!osb<Bl<!
• g{<gjt!-jlg<Gl<!
• lbqi<gjt!sqzqIg<gh<h{<[l<!
-bz<H!
8/! %Ile<!
• lekqzqVf<K!gqtl<hqg<!g{<{qzqVf<K!
-jljbg<!ogim<Muqg<Gl</!
• ogim<miuq!uqmh<h{<[l<!
• hzl<!d{<Mh{<[l<!
• g{<gjtk<kqxg<gUl<!&mUl<!h{<[l<!
• g{<gtqeqe<E!fQjv!uqps<osb<Bl<!
hzk<jk!
ogMg<Gl<!
9/! gqVgve<!
• fiuqx<gsqU!
• fisqbqz<!gsqU!
• hsq!d{<mig<Gl<!
• ye<jx!fqjek<kqVg<gs<!osb<Bl<!
• Kl<lz<!
• -Vlz<!
-bz<H!
:/! Okukk<ke<!
• Osil<hjzBl<!
• dmz<!Liqk<kjzBl<!d{<mig<Gl<!
• s{<jm!ogit<tz<!
• lqg<gOgihl<!d{<mig<Gl<!
Osil<hjzBl<!
dmz<!
Lxqk<kjzBl<!
d{<mig<Gl<?!
Osix<xqz<!ouXh<H!
21/! keR<osbe<!
• &g<gqzqVf<K!kck<K!dml<H!
LPjlBl<!uQr<gh<h{<[l<!
• gikqz<!gmz<!Ohiz<!-jvBl<!
• -xf<Kuqce<!gix<oxz<zil<!outqh<hm<m!
hqe<ei<!&e<xiuK!fitqz<!kjz!
ouck<khqe<!gie<!OhiGl</!
-bz<H!
 
! !
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hqk<kl<;< << << < !
u/w{<<<<!
hqk<kk<kqe<!< < << < << < <
ujggt<<<<!
osbz<<<<!
sm<jmg<!gvh<hieqz<!< < < << < < << < < <
d{<miGl<!< << << <
uqgx<hr<gt<< < << < << < <!
2/! nex<hqk<kl<!
• kQbqe<!h{<HjmbK!
• uqjvh<jhg<Gl<!hg<Guisbk<kqx<Gl<!
-jmbqzqVf<K!kQbqe<!G{k<jk!
lqGkqbigh<!ohx<X?!fQI!ucuLt<t!
ohiVt<gjt!uxts<!osb<Bl</!
• d{<m!d{ju!osiqg<Gl<!hcosb<Bl</!
-bz<H!
3/! -vR<sgh<hqk<kl<!
• osf<fQjv!lqGkqh<hMk<Kl<!
• -jvg<!GmzqzqVf<K!ogi{<M!
d{uqzqVf<K!hqiqf<K{<mie!siXg<Gs<!
osf<fqxk<jk!kVl</!
Okiz<!uxm<sq!
gi{h<hm<me!
4/! sikgh<hqk<kl<!
• klvgk<kqeqe<X!lel<?!hk<kq!hx<X!
-ux<jxg<!ogi{<M!uqVh<hlie!
okipqjzs<!osb<K!Lcg<Gl<!
upg<glie!h{q!
osb<b!-bzijl!
5/! NOzisgh<hqk<kl<!
• g{<gTg<G!ohiVm<gjt!okiquqg<Gl<!
• ohiVt<gtqe<!ucuk<jk!nxqkz<!
-bz<H!
6/! hqvisg!hqk<kl<!
• OkiZg<G!ytqjbogiMk<K!ytqvs<!
osb<Bl</!
gt<tqh<H,juh<!Ohiz<!
dml<ohz<zil<!
gqjtk<kz<?!
heqk<Ktq!Ohiz<!fQI!
gsqkz<?!Okizqe<!
ytq!Gjxkz<?!
Okiz<!gVfqxlikz</!
!
ghl<!;!<<< ! ! ! !
u/w{<<<<!
ghk<kqe<< << << <!
ujggt<<<<!
osbz<gt<< << << <!
sm<jmg<!gvh<hieqz<!< < < << < < << < < <
d{<miGl<!< << << <
uqgx<hr<gt<< < << < << < <!
2/! nuzl<hgl<!
• kQbqe<!h{<HjmbK!
• uqjvh<jhg<Gl<!
hg<Guisbk<kqx<Gl<!
-jmbqzqVf<K!kQbqe<!G{k<jk!
lqGkqbigh<!ohx<X?!fQI!
ucuLt<t!ohiVt<gjt!uxts<!
osb<Bl</!
-bz<H!
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• d{<m!d{ju!osiqg<Gl<!
hcosb<Bl</!
3/! gqOzkgl<!
• osf<fQjv!lqGkqh<hMk<Kl<!
• -jvg<!GmzqzqVf<K!ogi{<M!
d{uqzqVf<K!hqiqf<K{<mie!
siXg<Gs<!osf<fqxk<jk!kVl</!
sqzVg<G!hsqbqe<jl!
gi{h<hm<mK!
4/! Ohikgl<!
• klvgk<kqeqe<X!lel<?!hk<kq!hx<X!
-ux<jxg<!ogi{<M!uqVh<hlie!
okipqjzs<!osb<K!Lcg<Gl<!
-bz<H!
5/! kx<hgl<!
• g{<gTg<G!ohiVm<gjt!
okiquqg<Gl<!
• ohiVt<gtqe<!ucuk<jk!nxqkz<!
• OkiZg<G!ytqjb!ogiMk<K!
ytqvs<!osb<Bl<!
-bz<H!
6/! sf<kqgl<!
• OkiZg<G!ytqjbogiMk<K!
ytqvs<!osb<Bl</!
gQz<gt<!uzqk<kz<!
!
WP!dmx<kiKg<gt<< < << < << < <!
! WP! dmx<! kiKg<gTl<! kk<kl<! -bx<jg! h{<OhiM! =Vk<kze<xq! leqk!
dmz<! gQp<g{<m! WP! dmx<! kiKg<gtiz<! NeK/! ! nju! lqGf<OkEl<?!
Gjxf<OkEl<!hq{qgt<!Wx<hMl</!
u/w{<<<<! ujggt<<<<! osbz<gt<< << << <!
sm<jmg<!< << << < gvh<hieqz<!< << << <
d{<miGl<!< << << <
uqgx<hr<gt<< < << < << < <!
2/! sivl<!
• dmjzBl<?!lek<jkBl<!
Dg<gLxs<!osb<uK!
dmz<OsiIU?!
les<OsiIH?!d{uqz<!
ouXh<H!
3/! osf<fQI!
• nxqU?!ue<jl?!ytq?!osVg<G?!
yzq!-jugjt!fqjzg<gs<!
osb<Bl<!
Okiz<!uxm<sq?!Okiz<!
gVfqxl<!NGkz<!
4/! De<!
• dmzqe<!dVuk<jk!nke<!
okipqx<gq{r<g!njlk<kz<!
• we<jh!uti<k<kz<!
H{<!d{<mikz<?!
H{<{qzqVf<K!fQI!
gsqkz<?!!
5/! ogiPh<H!
• dXh<HgTg<G!ofb<h<Hh<!hjs!
Dm<c!gcelqe<xq!-bg<Gl<!
Okizqz<!ofb<h<H!hjs!
Gjxkz<!
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6/! we<H!
• dmjz!yPr<G!hm!fqXk<kq!
juk<kz<!
• ole<jlbie!dXh<Hgjth<!
hiKgik<kz<!
• dmz<!njsuqx<G!
nch<hjmbibqVk<kz<!
gQz<gtqz<!uzqk<kz<?!
we<H!sf<Kgtqz<!
OfiUl</!
7/! &jt!
• we<Hg<Gt<!fqjxf<K!njugTg<G!
ue<jlBl<!ole<jlBl<!kVl<!
-bz<H!
8/! Sg<gqzl</SOvi{qkl<! • gVk<Okix<xk<kqx<G!Lkzib<!fqx<hK! .!
w{<ujgk<Oki<Ugt<< < < << < < << < < <!
“w{<ujgk<!Oki<Ugtiue”!
“fich<!hiqsl<!fifqxl<!olipquqpq!
lzl<!&k<kqvlqju!lVk<KuviBkl<”!
olb<Gxq!fqxf<kokieq!uqpqfiuqVlzl<!jgg<Gxq!
.!Ofib<fimz<!Ofib<Lkeimz<!kqvm<M!higl<!.I!
u/w{<<<<! ujggt<<<<! sm<jmg<!gvh<hieqz<!d{<miGl<!uqgx<hr<gt<< < < < < < < < << < < < < < < < << < < < < < < < <!
2/! fic! uikhqk<kl<?!uikghl<?!hqk<k!uikl<!gi{h<hm<me/!
3/! ^<hiqsl<! okiMukx<G!ouh<hlig!-Vk<kz<!
4/! fi! -bz<H!
5/! fqxl<! hikqg<gh<hm<m!-mk<kqz<!Okiz<!gVfqxlikz<!
6/! olipq! -bz<H!
7/! uqpq! -bz<H!
8/! lzl<! lzg<gm<M!
9/! &k<kqvl<! jug<Ogiz<!fQiqe<!fqxl<!
!
fQIg<GxqQ <Q <Q < !
! sm<jmg<gvh<hie<< < < << < < << < < <!Ofibqz<!fQI?!jug<Ogiz<!fQI!fqxl<!gi{h<hm<me/!
fQI!ofb<g<GxqQ < <Q < <Q < < !
! “nvoue!fQ{<ce0Ok!uikl<!
! NpqOhix<!hvuqe<!n0Ok!hqk<kl<!
! Lk<okik<K!fqx<gqe<!olipquoke<!ghOl”!
• fQiqz<! uqMl<! yV! Ktq! w{<o{bieK! hil<jhh<! Ohiz<! fQ{<miz<!
uikOfiBl<?!!
• Olikqvl<!Ohie<X!-jmuqm<m!um<mlibqVf<kiz<!hqk<k!OfiBl<?!!
 18
• Lk<Kh<Ohiz<!nh<hcOb!-Vf<kiz<!Jb!OfiBliGl</!
• ohVl<hiZl<! sm<jmg<! gvh<hie<< < < << < < << < < <! Ofibqz<! ghfQI! ofb<g<GxqOb!
gi{h<hMgqe<xe/!
lzg<Gxq<<< !
! sm<jmg<!gvh<hie<< < < << < < << < < <!Ofibqz<?!!yV!sqzVg<G!lzs<sqg<gz<!gi{h<hm<me/!
hVugizr<gt<< << << <!
!! hVugizr<gt<!7!ohVl<ohiPKgjt!ogi{<mju!!
njubiue?!
giIgizl<! ! .!! Nu{q?!Hvm<misq!)August to October) 
%kqi<gizl<! ! .! Jh<hsq?!giIk<kqjg!)October to December) 
Le<heqgizl<!! .! lii<gpq?!jk!)December to February) 
hqe<heqgizl<!! .! lisq?!hr<Geq!)February to April) 
-tOueqz<gizl<! .!! sqk<kqjv?!jugisq!)April to June) 
LKOueqz<gizl<! .! Neq?!Nc!)June to August) 
 utq?!npz<?!Jbl<!we<El<!&e<X!Gx<xr<gTl<!giz!-bz<hiz<!liXhiM!
Wx<hMgqe<xe/!
! nju?!
• ke<eqjz!uti<s<sq!
• Oux<Xfqjz!uti<s<sq!
• ke<eqjzbjmkz<!
!
Lg<Gx<xl<< < << < << < <! ke<eqjzuti<s<sq< < << < << < < !
Oux<Xfqjz!<<<
uti<s<sq< << << < !
ke<eqjzbjmkz<< << << <!
uikl<! LKOueqz<gizl<! giIgizl<! %kqi<gizl<!
hqk<kl<! giIgizl<! %kqi<gizl<! Le<heqgizl<!
ghl<! hqe<heqgizl<! -tOueqz<gizl<! LKOueqz<gizl<!
!! !
!! -ke<!nch<hjmbqz<!uijz!gvh<hie<!Ofib<!Le<heqgizl<!)lii<gpq?!jk*?!
hqe<heqgizl<! )lisq?! hr<Geq*?! -tOueqz<gizl<! )sqk<kqjv?! jugisq*! Ngqb!
gizr<gtqz<!Okie<Xgqe<xe/!!
! !
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Jujg!fqzr<gt<!)kqj{*< << << < !
! GxqR<sq! .!! ljzBl<!ljz!siIf<k!-mLl<!
! Lz<jz! .! giMl<!giM!siIf<k!-mLl<!
! lVkl<!! .! ubZl<!ubz<!siIf<k!-mLl<!
! ofb<kz<! .! gmZl<!gmz<!siIf<k!-mLl<!
! hijz!! .! l{Zl<!l{z<!siIf<k!-mLl<!
!! sm<jm! gvh<hie<< < << < << < <! OfibieK! ofb<kz<! fqzk<kqz<! dt<tui<gTg<Og! uVl<!
OfiobeqEl<?!lVk!fqzk<kqz<!dt<t!Gpf<jkgTl<!hikqg<gh<hm<Mt<tei</!
hq{qbxqLjxjl!
! hq{qbxqLjxjl!we<hK!dmjzh<!hq{qk<kzib!Ofijbk<!okiqf<K!
ogit<Tgqx!yPg<gl<!weh<hMl</!
nju?!
2/ ohixqbiz<!nxqkz<!
3/ Hzeiz<!nxqkz<!
4/ uqeikz<!
2/ohixqbiz<!nxqkz<< << << <!
! ohixqbiz<!nxqkzqz<!fig<gieK!)uib<*!H{<!Wx<hm<Ml<?!OkizieK!)olb<*!
H{<gt<?!fQIgsqkz<?!uxm<sq!Lkzqbe!Wx<hm<Ml<!gi{h<hm<me/!
3/!Hzeiz<!nxqkz<< << << <!
! Hzeiz<!nxqkzqz<!fix<xlieK!)l{l<*!H{<gtqz<!heqfQI!hib<f<K!
fix<xLl<?!DX!dml<hqz<!osixq!Ohie<Xl<!gi{h<hm<me/!
4/!uqeikz<<<<!
! uqeikzqz<!Ofib<!Wx<hm<m!uvziXl<?!Ofib<g<gie!Lke<jl!giv{k<jkBl<!
Ogm<M!nxqbh<hMl</!
lVk<Ku!upqLjx;<<< !
2/ uikGx<xl<!hikqh<H!njmf<Kt<tkiz<?!ng<Gx<xk<jk!
ke<eqjzh<hMk<kg<%cb!Ohkq!lVf<jk!ogiMg<g!Ou{<Ml</!
3/ hqe<ei<!dt<lVf<K?!outqlVf<K!ogiMk<K!Ofijb!fQg<g!Ou{<Ml</!
4/ hk<kqbl<!gig<g!Ou{<Ml</!
5/ keqk<K~b<jl!yPg<gk<jk!gjmhqcg<g!nxqUjv!osb<b!Ou{<Ml</!
!! sqk<ki<gt<! Ofib<! -z<zik! uip<g<jg! Ljxg<G! gjmh<hqck<k!
lVk<Ku!upqLjxgt<?!
 gih<H!!
 fQg<gl<!
 fqjxU!Lkzqbe!NGl</!
! !
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Gx<xk<jk!ke<eqjzhMk<kz<< < < < << < < < << < < < <!
sm<jm!gvh<hieqz<!utqGx<xl<!hikqh<hjmgqxK/!
“uiklziK!Oleq!ogmiK”!
. OkjvbI!
!! utqg<Gx<xk<jk!ke<eqjzh<hMk<k!Ohkq!lVf<jk!ogiMg<g!Ou{<Ml</!
! “uqOvsek<kiz<!uikl<!kiPl<”/!
! OhkqlVf<K! Okjuh<hm<m! dt<Ofibiti<! lx<Xl<! outqOfibiti<!
Gpf<jkgTg<G! lm<Ml<! ! Okgue<jljb! gVk<kqz<! ogi{<M! fqzuijgs<S,v{l<!
4gqvil<!-vU!yV!Oujt!lm<Ml<!ouf<fQiqz<!ogiMg<gh<hm<me/!
dt<lVf<K< << << < !
! gvh<hie<!GcfQi<!-v{<M!Oujt!ogiMg<gh<hm<mK/!
ntU;!
! gvh<hie<! GcfQi<! Gpf<jkgtqe<! Okgfqjz?! gizfqjz! lx<Xl<! ubK!
Ngqbux<jx! ohiXk<K! lVf<kqe<! ntU! fqi<{bqg<gh<hm<mK/! ! ohiKuig!
gQp<gi[l<!ntUgtqz<!lVf<Kgt<!kvh<hm<mK/!
! ubK!! ! ! ntU!
! 4!.!8!ubK! ! .! 41!lq/zq!
! 8.23!ubK! ! .! 71!lq/zq!Ng!-v{<M!Oujt!!
d{Ug<G!hqe<!kvh<hm<mK/!
outqlVf<K<<< !
! gvh<hie<! w{<o{b<! hikqg<gh<hm<m! Gpf<jkgTg<G! outqh<H,s<sig! kmu!
ogiMg<gh<hm<me/!
hk<kqbl<< << << <!
! Ositl<?! gl<H?! uvG?! uijpg<gib<?! higx<gib<?! ogtqx<XlQe<?! ogit<T?!
olis<js?! ngk<kqg<gQjv?! gVuiM?! gk<kqiqg<gib<! Ohie<x! gvh<hie<! Ofibqe<!
kQuqvk<jk!lqGkqh<hMk<kg<%cb!hkiIk<kr<gt<!d{uqz<!-Vf<K!kuqi<g<g!nxqUjv!
%xh<hm<mK/!
nxqUjv!
2/ sUg<giv!gm<cjb!kuqi<k<K!fZr<Gli?!hisqh<hbX!-ux<jx!Gtqg<Gl<OhiK!
dhObigqg<Gl<hc!%xh<hm<mK/!
3/ Okr<gqb!fQIfqjzgtqz<!Gtqh<hjk!kuqi<g<GliX!nxqUXk<kh<hm<mK/!
4/ ke<!Sgikivl<!hqe<hx<x!nxqUXk<kh<hm<mK/!
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MODERN ASPECTS 
ATOPIC DERMATITIS 
Introduction: 
  The term ‘atopic’  was coined by coca and cooke. The diseases was named as 
“Atopic Dermatitis” by sulzberger and co-workers. 
  Atopic dermatitis is an endogenous dermatitis triggered by exogenous agents 
and is characterized by 
• Extremely pruritic recurrent, symmetric eczematous lesions. 
• Typical sites of involvement, depending on age of patient. 
• Personal (or) family history of atopic diseases  
• Increased ability to form IgE (reaction) to common environemntal 
allergens. 
Epidemiology 
• Seen in 3% of all infants 
• Begins between 3-6 months of age 
• World wide incidence increasing because of  
a. Increased exposure to pollutants 
b. Increased exposure to indoor allergens (especially house dust 
mite) 
c. Decline in breast feeding. 
Aetiology and pathogenesis 
 AD results from complex interaction between genetic susceptibility (resulting 
in defective skin barrier) and immunological changes (abnormalities of lymphocytes 
with a heightened IgE response to environemental and microbial antigens) 
Genetic susceptibility 
• Genetic predisposition very important, but precise mode of inheritance 
uncertain, may be autosomal dominant. 
• Atopic disease run true to type within each family in some families, 
members predominantly have dermatitis. while in other families 
respiratory symptoms predominate.  This is probably because dermatitis 
and asthma are inherited through separate but closely associated genetic 
pathways. 
• HLA typing, however, does not support genetic inheritance. 
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Defective skin barrier 
Impaired skin barrier function plays a key role in pathogenesis of AD, 
• Allows increased transepidermal water loss (TEWL) 
• Allows entry of allergens, antigens and chemicals from the environment 
and these trigger inflammatory response in the skin. 
 
Fig.No.1 
Immunological changes 
Abnormalities of lymphocytes 
1. Acute phase of AD.  Is associated with production of T-helper 2(Th2) 
cytokines (II-4 and II-3) 
2. Chronic phase of AD: Is associated with production of Th1 cytokines (IFN- γ) 
3. Deficiency of resident treg cells. 
Increased IgE levels  
Abnormalities of IgE: Include 
 Elevated  IgE levels (>80% patients with AD have IgE levels >200 iU/ml). 
 Increased specific IgE to multiple allergens, because AD is characterized by 
increased production of IgE in response to foods, aeroallergens, microbes and 
their toxins. 
 Increased expression of IgE receptors on β cells. 
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Causes of elevated levels of IgE.  The exact cause is not known but may be due 
to: 
• Defective control of IgE production by T-lymphocytes 
• IgE overproduction to a variety of antigenic challenges 
• Role of IgE: Antigens attach to IgE on surface of mast cells leading to 
their degranulation resulting in release of mediators of inflammation into 
tissues. 
Psychological factors: 
  Atopic dermatitis has tremendous psychological effect on an affected 
individual.  In children, it has been found that a hyper responsive hypothalamic – 
pituitary – axis (HPA) bluts the body’s capability to produce cortisol during the 
period of stress.  The resultant inability to suppress inflammatory response leads to 
aggravation of the eczema. 
Clinical features 
  AD is a chronic disease punctuated by acute flares.  Three distinct patterns of 
AD have been recognized depending on age of the patient. 
 
Fig.No.2 
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Phases of atopic dermatitis 
AD in infants 
• Begins after age of 3 months 
• Intensely itchy, grouped papules and vesicles, which soon become 
exudative  
• Begins on the face but can involve rest of  the body.  Sparing diaper area. 
• Secondary infection is common 
• Runs a chronic course 
o In 40% of infants, lesions clear by age of 18 months. 
o In 60% pattern changes into childhood pattern. 
AD in children 
• Extremely itchy, dry, leathery plaques. 
• Mainly on elbow and knee flexors often a reversed (extensor) pattern seen. 
AD in adults 
• Intensely itchy, lichnenified plaques. 
• Cubital and popliteal fossae and sometimes the neck. 
• A low-grade involvement may be seen in different parts of the body. 
Eg:  Lick cheilifis 
 Nipple eczema 
 Hand dermatitis 
 Nummular dermatitis 
Associated features 
 Other atopic manifestations: About 50% patients with AD have allergic 
rhinitis and about 30% have asthma.  In patients with both asthma and dermatitis, 
there may be an inverse relationship between the two. 
 Urticaria: Atopics also develop ford allergies and uticaria more frequently. 
Others:  
  Several other associations are reported and these may help in making a 
diagnosis of AD. 
Special features: 
• Atopic dermatitis patients have a tendency to develop generalised 
infections, especially herpes simplex superimposed staphylococcal 
infection is also frequent 
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• While dermographism on stoking involved skin and or delayed blanch to 
cholinergic agents. 
• Bilateral cataracts occur in upto 10% in the more severe cases, the peak 
incidence is between 15 years and 25 years of age. 
• Ichthyosis vulgaris and keratosis pilaris are present in 10% of children 
• Periorbital pigmentation, Infra orbital fold in eyelids (Dennie – Morgan 
sing) and loss of lateral portions of eyebrows (hertoghi’s sign) may be 
present in some. 
 
FLARE REACTION 
Contact dermatitis 
• This form of eczema can be sub divided into irritant dermatitis resulting from 
non specific injury to the skin and allergic contact dermatitis in which the 
mechanism is a delayed hypersensitivity reaction.  Irritant dermatitis is more 
frequent in children, particularly during the early years of life. 
• Irritant contact dermatitis can result from prolonged (or) repetitiue contact 
with various substances that include saliva, citrus juices, bubble both, 
detergents, abrasive materials, strong soaps and proprietary medications.  
Saliva is probably one of the most common offenders,  It may cause dermatitis 
on the face and in the neck folds of a drooling infant or a retarded child. 
• Other children who habitually lick their lips, frequnetly without awareness 
because of dryness may develop a striking.  Sharply demarcated periceral rash.  
Among the exogenous irritants, citrus juices, proprietary medications and 
bubble bath preparations are relatively common. 
• Irritant contact dermatitis usually clears after removal of the stimulus and 
temporary treatment with a topical cortico steroid  preparation education of 
patients and their parents about the causes of contact dermatitis is crucial to 
successful therapy. 
Diaper dermatitis 
• Diaper dermatitis can be regarded as the prototype of irritant contact 
dermatitis as a reaction to over hydration of the skin, friction, maceration and 
prolonged contact with urine and faeces, retained diaper soaps and topical 
preparation, the skin of the diaper area may become erythematous and scaly, 
often with papulovesicular (or) bullous lesions, fissures and erosions.  The 
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erosion can be patchy or confluent but the genitocrural folds are often spared.  
Chronic hypertrophic flat topped papules and infiltrative nodules may occur.  
Secondary infection with bacterial or yeast is common.  Discomfort may be 
marked because of intense inflammation. 
• The damaging effects of over hydration of the skin and prolongs contact with 
feces and urine can be obviated by frequent changing of the diapers.  
Overwashing should be avoided because it leads to chapping and a worsening 
of the dermatitis.  Disposable diapers containing a super absorbent material 
may help to maintain a relatively dry environment.  frequent topical 
applications of a bland protective barrier agent (petrolatum of zinc oxide 
paste) may suffice to prevent dermatitis. 
Juvenile plantar dermatosis 
  Juvenile plantar dermatosis is a common form of irritant contact dermatitis 
occuring mainly in prepubertal children.  The dermatitis characteristically involves  
the weight bearing surfaces, may be pruritic or painful and causes aglazed appearance 
of the plantar skin.  Fissuring may become extensive, producing considerable 
discomfort.  The dermatitis results from alternating excessive hydration and rapid 
moisture loss, which causes chapping of the skin and crackling of the stratum 
carneum.  Affected children often have a hyperhidrosis, wear occlusive synthetic 
footwear and subject their feet to rapid drying without moisturization.  Immediate 
application of a thick emollient, when socks and shoes are removed or immediately 
after swimming usually minimizes this condition. 
Diagnosis 
  For routine clinical work, diagnosis of AD is based on. 
• Presence of an itchy skin condition (or parental report scratching or 
rubbing in a child.) 
Plus 3 
• Onset <2 years of age (not used if child is under 4 years) 
• History of skin crease involvement (including cheeks in children under 10 
years). 
• History of a generally dry skin. 
• Personal history of other atopic disease (or) history of any atopic diseases 
in a 1st degree relative in children under 4 years. 
• Visible flexural dermatitis (or dermatitis of cheeks/forehead and outer 
limbs in children under 4 years). 
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DIAGNOSIS OF ATOPIC DERMATITIS 
 Hanifin and Rajka’s criteria for diagnosis of atopic dermatitis. 
S.No 
Major features 
 (must have 3 or more) 
Minor Features  
(must have 3 or more) 
 Pruritus 
Typical morphology & 
distribution 
i. Facial  & extencer 
involvement in 
infants & children. 
ii. Flexural 
lichenification in 
adults.  Dermatitis, 
chronic (or) 
chronically relapsing 
personal (or) family 
history of atopy 
(asthma, allergic 
rhinitis (or) atopic 
dermatitis.) 
 
Cataracts (anterior subcapsular) 
Cheilitis 
Conjunctivitis (Recurrent) 
Facial paller/erythema 
Food intolerance 
Hand dermatitis, non-allergic  & 
irritant 
Ichthyosis 
Elevated level of IgE 
Immediate (type-1) skin test 
reactivity infections 
Itching, when sweating 
Keratoconus 
Keratosis pilaris 
Nipple dermatitis 
Orbital darkening 
Palmar hyperlinearify 
Perifollicular accentuation 
Pityriasis alba 
White dermographism 
Wool intolerance 
Xerosis 
 
 
Differential diagnosis 
In childhood 
Seborrheic dermatitis 
 Scabies 
 Tinea corporis 
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In adult 
Lichen simplex chronicus 
 soriasis 
 Scabies 
 Lichen planus 
 Tinea corporis 
 Airbone contact dermatitis 
 Allergic contact dermatitis 
Infantile seborrheic dermatitis 
 Infantile seborrheic dermatitis AD in infants 
Onset Infants < 3 months Infacnts >3 months 
Symptoms Asymptomatic Extremely itchy 
Distribution Scalp, major flexures caxillae, 
grains & trunt 
Face & other parts of body may 
begin like seborrheic dermatitis. 
Associations  Family or personal history of 
atopy 
b. Scabies 
 Scabies in infants AD in fants 
Morphalogy Papulovesicular lesions & 
burrous 
Papulovesicular lesions 
Distribution  Characteristic involvement 
palms, soles & faces and other 
parts 
Faces & other parts of body.  
Spares palms & scales & diaper 
area. 
Associations Typical lessions in family 
members 
Atopic diathesis in family. 
c. Airbone contact dermalitis (ABCD) 
 ABCD AD in infants 
Morphalogy Lichenified plaques Lichenified plaques 
Distributions Face (Prominent involvement)& 
flexures 
Flexures, face relatively spared 
Associations Positive patch test Family history of atopy: dry 
skin, nipple, eczema & 
nummular dermatitis. 
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Laboratory examination 
i. Increased IgE in serum 
ii. Culture and sensitivity for bacterial infection 
iii. Culture for HSV if indicated 
Investigations/Dermatopathology 
  Changes are seen in the epidermis and dermis.  There are varying degrees of 
acanthosis with rare intraepidermal intercellular edema (Spongiosis).  The dermal 
infiltrate is comprised of lymphocytes, monocytes and mast cells with few (or) no 
eosinophils. 
Patch test 
 A standard battery of common allergens in very dilute concentration is put on 
as patch on patients skin surface, usually on back in FIN.  CHAMBER, reading is 
taken after 48 and 72 hours to see my reactions (erythema, vesuculation etc) 
 Patch test can identify incriminating  and differentiate from non allergic 
irritant dermatitis. 
Photo patch test 
 At 24 hours, a duplicate patch is put after irradiating to UVR in minimum 
erythema dose the test determines photo allergic contact dermatitis from other form of 
eczematous dermatitis. 
Serological test 
 Level of total IgE and IgE to specific allergens will help atopic dermatitis and 
will also guide the outcome and prognosis of the patients. 
Prick testing 
 Can identify type one hypersensitivity reaction, false-positive reactions limit 
the utility of the test. 
Skin biopsy 
 Skin biopsy may be advised to differentiate eczematous dermatitis from 
psoriasis, lichen planus etc. 
Treatment 
General 
 The most important aspect of the management of a child with atopic eczema is 
sympathetic explanation of the nature of the condition to its parents. 
 Education of the patient to avoid rubbing and scratching is most important. 
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 Topical preparations are valuable but are useless if the patient continues to 
scratch and rub the plaques, topical antipruritic (Menthal/ camphor) lotions are 
helpful in controling the pruritus. 
 Warn parents of the special problems with herpes simplex and frequency of 
superimposed staphylococal infection. 
 
 
Fig.No.3 
Specific 
 H1 anti histamines are probably useful in reducing itching. 
 Hydration (oiled baths) followed by application of unscentred emullients 
(eg.hydrated petrolatum) is a basic daily treatment needed to prevent 
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xerosis.  Soaps showers are permisible in order to wash the body folds, but 
soap should not be used on the other parts of the skin surface. 
 Topical and anti-inflammatory agents, such as corticosteroids, hydra 
oxyquinoline preparations and tar are the mainstays  of treatment of these, 
corticosteroids are the most readily accepted by the patient. 
 Systemic corticosteroids should be avoided, except in rare instances for 
only short courses. 
 Children should be taught to use stress management techniques. 
Advice 
1. Climate 
Moderate temperature is best to help recovery. 
Avoid extremes of climate, because increased heat and increased sweating, 
increases eczema. 
2. Bath 
 In winter-patients advised to take warm starch bath. 
 In summer-patients are advised to take cold condy’s bath. 
After bath – blot with a smooth towel and avoid rubbing. 
Dry skin – Olive oil, banoline cream, butter (or) ghee massage to helps to 
lubricate the skin. 
3. Patients should not scratch and keep his nails short. 
i. Splints should be employed 
ii. Sedatives given at right. 
4. Diet 
 a. Diet should be simple 
b. Disseminated eczema  Advice to take light food for a few days to help the    
    body to get rid of toxic substances. 
c. Allergic eczema :Eliminative diet (Avoid allergenic food stuffs). 
5. Healthy hobbies. 
6. Any side effect 
 While taking medication any side effects should be reported to the physician. 
7. Local medications  should be preparely employed. 
8. Rest 
 Rest to the affected part recommended 
 Bed rest is necessary to accelerate healing. 
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9. Protection 
a. Protection of the affect part is desirable. 
b. Exogenous eczema-use cotton bandage, glove. 
10. Internal & systemic therapy 
 A few western drugs are available they give symptamatic relief only 
a. ACTH and corticosterodis eg: prednisolone. 
b. Anti-histaminies – control itching  
c. Calcium gluconate 
d. Antibiotics-infective eczema 
e. Sedatives and hypnotics 
f. General tonics – multivitamins, iron, liver extract. 
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4. MATERIALS AND METHODS 
 
  To find the efficacy of Karappan Kudineer Chooranam (Internal) and 
Karappan Ennai (External), the following studies were carried out in the present 
investigation. 
1. Collection, Identification and confirmation of the raw drugs, for the 
preparation of trail drug 
2. Preparation of trail drug 
3. Biochemical analysis of trail drug 
4. Pharmacological studies of trail drug. 
5. Clinical trail 
        The clinical study on “SATTAI KARAPPAN” is being conducted in the 
outpatient and inpatient postgraduate department of KuzhanthaiMaruthuvam at 
Government Siddha Medical College Palayamkottai. 
Selection of cases 
 Patients reporting with symptoms of inclusion criteria will be subject to 
screening test and documented using screening proforma. 20 inpatients and 20 
outpatients are select. In patients will be given medicine and provided hospital diet. 
Outpatients provide medicine and dietary regulations. 
Inclusion criteria 
 Age  : 3 to 12 years 
 Sex  : Both male and female children 
 Intense itching 
 Erythema 
 Papules 
 Papulovesicles 
 Crusted lesion all over the body 
 Ulceration 
 Exudation 
 Constipation 
Exclusion criteria 
 Children above 12 years 
 Scabies 
 Psoriasis 
 Secondary bacterial infection 
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 Nummular dermatitis 
 Contact dermatitis 
 Seborric dermatitis 
 Furunculosis 
 Photodermatitis 
 Neurodermatitis 
Withdrawal criteria 
 Occurrence of any adverse effects. 
 The drug not responding to the condition. 
 Exacerbation of symptoms. 
 Patients unbelieve to continue in the course of trial. 
Study of Siddha clinical diagnosis 
 A case sheet was prepared on the basis of Siddha methodology and modern 
methodology to diagnose the disease. An individual case sheet was maintained for 
each and every patient. 
 A complete history of the patient was taken. Name, Age, Sex, History of 
present and past illness, Antenatal, Neonatal and postnatal history, personal and 
dietetic history, family history and Socio-economic status were noted. 
 Siddha diagnosis was made on the basis of Envagaithervugal, Mukkutram and 
Ezhuudalkattukal. 
 Modern diagnostic methods were adopted with the consultation of pediatric 
professor. 
Tests and assessments 
• Siddha tests and assessment 
Mukuttram 
Udalkattukal 
Envagaithervugal 
Neerkuri 
Neikuri 
• Clinical assessment 
Pruritis 
Itching 
Erythema 
Papules  
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Papulo vesicles 
Crusted lesion 
Oozing  
 Bleeding  
 Ulceration 
Laboratory assessment 
  The Modern diagnostic tests such as blood test for TC, DC, ESR, Hb, Skin 
scrapping test etc., urine analysis for albumin, sugar, deposits, etc., and stool 
examination for ova, cyst, occult blood to rule out any existing illness. 
Hemoglobin was estimated before and after therapy. 
Administration of Trial Medicine: 
    The trial drug was prepared carefully. 
 Before starting the treatment deworming was done with Nilavagaichoornam – 
3gms Od at night with hot water for 3-5 days. “KARAPPAN KUDINEER 
(INTERNAL) 5ml after food and KARAPPAN ENNAI (EXTERNAL) for 21 days  
intake was given to all the 40 patients two times a day during their treatment period. 
1. Karappan Kudineer (Internal Medicine) 
Age Dose 
3 – 7 Years 30ml 
7 – 12 Years 60ml 
2. Karappan Ennai (External Medicine) 
 The Biochemical analysis of trial drug was carried out in the biochemical 
laboratory and the  Anti-inflammatory, Anti-histamine effect, Acute toxicity study 
and dermal toxicity study of the drug was tested in the pharmacological laboratory. 
 Analysis of observations made from the 20 patients with signs and symptoms 
of the disease were recorded. In addition to medicine the patients were advised to take 
banana, potato, rice milk, buckwheat, green onions and to attend the out patients 
department for follow up 
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PREPARATION & PROPERTIES OF THE TRIAL DRUG 
gvh<hie<!GcfQI!$v{l<< < Q << < Q << < Q <!
OsVl<!svg<Ggt<< < << < << < <!
osr<gk<kiiq!hm<jm!!.!211!gq!
lqtG!! ! .!211!gq!
sqe<eq!-jz!! .!211!gq!
sqXGxqR<sie<!Oui<! .!211!gq!
! ! ! ! .!Okjvbi<!GcfQI!hGkq.3!hg<gl<;53!
!
svg<Ggtqe<!Sk<kq!Ljx< < << < << < < !
hm<jm<<< !;!! lQk<Okijzs<!Sv{<ch<!Ohig<gqg<!ogit<ts<!Sk<kqbiGl</!
-jz!;! -jzgtjg<!gqjtbqeqe<X!ogib<K!fQiqzqm<M!nzl<hq!fQjv!fe<G!!
uck<K!wMk<Kg<!ogit<tzil</!
lqtG!;  Htqk<k!Oliiqz<!ye<Ox!giz<!l{q!Ofvl<!Dxh<Ohim<M!uXg<gs<!!
Sk<kqbiGl</!
Oui<<<<! ;!! K~b!fQiqx<!gPuq?!Ouiqz<!ym<cb!l{<Ohig<gq!wMk<Kg<!ogit<t!!
Ou{<Ml</!
osb<Ljx<<< !
! Sk<kq! osb<k! lVf<K! svg<Ggjt! ntuig! fQIuqm<Mg<! gib<s<sq! uck<K!
-Xk<Kh<!hVGg/!
ntU!! !
ubK!! ! ntU!
!4!.!8!! !! 41lqzq!
!8!.!23! ! 71lqzq!
Ng!-v{<M!Oujt!d{Ug<G!hqe<!ntqg<gh<hm<mK!
kQVl<!Ofib<Q < <Q < <Q < <! ;!gvh<hie<!
NBm<gizl<< << << <! ;!4!likr<gt<!
! !
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gvh<hie<!w{<o{b<< < < << < < << < < <!
OsVl<!svg<Ggt<< < << < << < <!
! Htqbl<!-jz!! .! 63/61gq!
! Nuijv!Oui<hm<jm! .! 63/61gq!
! lqtG!! ! .! 63/61gq!
! gVR<sQvgl<! ! .! 63/61gq!
usl<H!Sm<mgiq! .! 63/61gq!
giIOhig!niqsq! .! 63/61gq!
wt<ot{<o{b<! .! 461lqzq!
NMkQ{<mih<hijts<siX!–!!Okjubie!ntU!
.!sqgqs<sivk<f< << << < !kQhl<!hGkqQ <Q <Q < .3!hg<gl</316< << << < !
Sk<kqgt<<< <!
-jzgt<<<<!
! -jzgt<! ohiqb!ntuqekieiz<!njugtqz<! hPh<hieju?!nPgqbju?!
dbqiqgt<?! kqe<xju! Lkzqbjugjt! fQg<gquqm<M?! K~b! K{qbiz<! fz<z!
-jzgjt! Kjmk<Kg<! gil<H?! fvl<H?! fQg<gq! wMk<Kg<! ogit<tzil</! ! sqxqb!
-jzgjtg<! gqjtbqeqe<X! ogib<K! fQiqzqm<M! nzl<hq! fQjv! fe<G! uck<K!
wMk<Kg<!ogit<tzil</!
!
hm<jm;<<< !!
!! lQk<Okijzs<!Sv{<ch<!Ohig<gqg<!ogit<ts<!Sk<kqbiGl</!
!
Oui<;< << !!
!! K~b!fQiqx<!gPuq?!Ouiqz<!ym<cb!l{<Ohig<gq!wMk<Kg<ogit<tOu{<Ml</!
!
lqtG!;   
  Htqk<k!Oliiqz<!ye<Ox!giz<!l{q!Ofvl<!Dxh<Ohim<M!uXg<gs<!Sk<kqbiGl</!
!
usl<H<<< !
! k{zqzqm<M! Sm<M! wiqf<kKl<! l{Zg<Gt<! Hjkk<K! n{jz! Nx<xqg<!
giqbig<gqg<!ogit<t!Ou{<Ml</!
!
gVR<sQvgl<< Q << Q << Q <!
! S{<{k<!oktqfQiqz<!Dxjuk<K!dzi<k<kq!wMk<Kg<!ogit<tzil</!
!
!
!
!
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giIOhig!niqsq!
! kqVfQx<Xh<!hs<sqjzs<!six<xqz<!fjek<K!Kzi<k<Kg!
. sqgqs<sivk<kqe!kQhl<!higl<!.!8!
osb<Ljx<<< !
! Htqbl<! -jz?! NuijvOuIhm<jm?! lqtG?! gVR<sQvgl<?! usl<H! Sm<mgiq?!
giIOhig!niqsq!-ux<jx!NMkQ{<mihijts<!six<xqz<!njvk<K!wt<ot{<o{bqz<!
gzg<gq!&e<X!fit<!uqvuq!Lgk<kqz<!juk<K!wMg<gh<hm<me/!
!
hqvObigl<<<<!
! outqh<hqvObigl<!
kQVl<!Ofib<Q < <Q < <Q < <! ! ;! gvh<hie<!
NBm<gizl<< << << <! ! ;!! 2!N{<M!
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5. DRUG REVIEW  
gvh<hie<!GcfQI!$v{l<< < Q << < Q << < Q <!
2/!osr<gk<kiiqhm<jm< < << < << < < !
Botanical name : Capparis sepiaria 
Family   : Capparaceae 
Part used  : Bark 
Sju! ! ! ;! jgh<H!
ke<jl! ! ;! ouh<hl<!
hqiqU! ! ! ;! giIh<H!
osb<jg<<< !
! Kui<h<hq! ;!Astringent 
 dvlig<gq! ;!Tonic 
 ouh<hL{<mig<gq!–!Stimulant 
G{l<<<<!
! “osr<gk<kiiqs<!gjmg<Gk<!kQvik!ue<Olgl<!
! ohir<gq!uVgqvf<kqh<!H{<Hjvgt<!kr<Ggqe<x!
! sf<kqg!sqOz]<lf<!keqk<k!lgiuik!
! Lk<kqjg!uqm<OmiMl<!olipq/”!
hqvOlfQI?! ym<MH{<?! Hjvgt<?! gQz<uQg<gl<?! uikOfib<?! fQiqpqU! Ohil</!!
hqvOlgl<?! OlgfQI?! k{<MuQg<gl<?! HjvObicb?! gqvf<kqh<H{<?! sqvr<G?! sqvr<Gh<H{<?!
niq?! osixq?! fjls<sz<?! uikl<?! wiquikl<?! jg?! giz<?! Gjms<sz<?! fjls<sz<!
-jubiUl<!fQr<Gl</!
 
Chemical constituents 
 Beta sitosteryl glucoside-6-octadae anoate(1) 
 3-methyl2-butenyl-beta – glucoside. 
 Alkaloid – cadabicine.!
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3/!lqtG!
Botanical name : Piper nigrum 
Family   : Piperaceae 
Parts used  : uqjk?!ohic!
Sju! ! ! ;! jgh<H?!giIh<H!
ke<jl! ! ;! ouh<hl<!
hqiqU! ! ! ;! giIh<H!
osb<jg<<< !
 ngm<Muib<ugx<xq!)Carminative) 
 Ljxouh<hgx<xq! )Antiperiodic) 
 kch<H{<mig<gq! ! )Rubefacient) 
 ouh<hL{<mig<gq!)Stimulant) 
 uQg<gr<gjvs<sq! ! )Resolvent) 
 uiklmg<gq! )Antivatha) 
 fs<siq! ! ! )Antidote) 
Chemical constituents 
 Piperine, α-tocophenal, α-pinene, β-cargophyllene, β-pinene, β-eudesmal, 
limonene, Delta-3carene, sabinene, Eugenol, Terpenin-4-ol, Hedycaryal, 
caryophyllene oxide. 
 Phytochemicals includes amides, piperidines, pyrrolidines and trace amounts 
of safrale. 
 Also contains, lysine, hitidine and cystine. 
G{l<<<<!
! ntjuBxig<givl<!njmf<kqVg<Gl<!uik!
uqjtjuobz<!zilXg<Gl<!olb<Ob!–!lqtgqe<gib<!
! g{<mui<g<Gl<!-e<hlil<!giiqjgOb!–!sQp<&zr<!
! ogi{<mui<g<G!fe<lVf<kir<!%X/!
!
!! -K!utqOfib<gjtBl<!sQp<!&zk<jkBl<!fQg<Gl</!
! !
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4/!sqe<eq!-jz<<< !
Botanical name : A calypha fruiticosa 
Family   : Eupharbiaceae 
Parts used! ! ;! -jz?!Oui< 
Sju!   : jgh<H  
ke<jl! ! ;! ouh<hl<!
hqiqU! ! ! ;! giIh<H!
osb<jg<<< ! ! !
 osf<fQiqtg<gq!)Attenuant) 
 dmx<Oxx<xq!)Alterative) 
 hsqk<kQk<K~{<c!)Stomachic) 
 fs<Sh<Ohig<gq!)Alexipharmic) 
Chemical constituents 
 Triterpenoids, steroids, saponins, Tannins, phenols, flavonoids, alkaloids, 
anthraquinones and sugars, β-caryophyllene, α-humulene, iso caryophyllene and 
caryophyllene oxide. Trans-phytol. 
G{l<<<<!
! gcuq]L!gi{ig<gcuq]Llik!
! iqMuq]LOliM!lqKue<xq!–ofcb!uqpqg<!
! ge<eqjgOb!Olgr<!g{g<gis<sz<!lif<kLl<!OhiR<!
! sqe<eqbqjzg<Gk<!okxqk<K/!
lf<kl<?!osiqbilf<kl<?!sqvr<G?!H{<?!osixq?!Nvikv{l<?!hsqbqe<jl?!Vsqbqe<jl?!
ng<gqeqlf<kl<?!N{<Gxq!v{l<?!oum<jm?!lzi<h<H{<?!hqvOlgl<?!out<jt?!yPg<G?!
sQp<Olgl</!
! !
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5/sqXGxqR<sie<!Oui<< < << < << < <!
Botanical name : Gymnema syluestre 
Family   : Apocynaceae 
Parts used! ! ;! -jz?!Oui<!
Sju!   : jgh<H  
ke<jl! ! ;! ouh<hl<!
hqiqU! ! ! ;! giIh<H!
osb<jg<<< ! ! !
 Kui<h<hq!)Astringent) 
 Ogijpbgx<xq!)Expectorant) 
 uif<kqB{<mig<gq!)Emetic) 
 
Chemical cosntituents 
 Flavones, anthraquinones hentri-acontane, pentatria contane, α & 
βchlorophyylls phytin, resins, d-quescital, tartaric acid, formic acid, butyric acid, 
lupeal, β-amyrin, glycosides and stigmasterol. 
 
G{l<!
! sqXGxqR<si!Oui<uq]k<jkk<!kQIg<g!lieqzk<!
! KXgvr<!gt<uik!olipqg<Gf<!.!okxqbi{g<!
! g{<{i!bqVle<Lkx<!gisf<!k{qg<Gl<!
! uq{<{i!hVg<Glqjkuqt</!
nx<hSvl<?! sqz<zjx! uq]g<gcgt<?! uikl<?! uikg<gMh<H?! Gkquikl<?!
Lguikl<?!&m<Muikl<?!Kl<lz<?!kjzhivl<?! fQIg<Ogiju?!stqgm<cb!uxm<cVlz<!
-ju!biUl<!fQr<Gl</!
!
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gvh<hie<!w{<o{b<< < < << < < << < < <!
2/!gVR<sQvgl<< Q << Q << Q <!
Botanical name : Nigella sativa 
Family   : Ranunculaceae 
Parts used! ! ;! uqjk!
Sju!   : jgh<H?!Kui<h<H!
ke<jl! ! ;! ouh<hl< 
hqiqU! ! ! ;! giIh<H!
osb<jg<<< !
 ngm<Muib<ugx<xq!)Carminative)!
 sqXfQIohVg<gq!)Diuretic)!
 VKU{<mig<gq!)Emmenogogue)!
 hix<ohVg<gq!)Galactogogue)!
 HPg<ogiz<zq!)Anthelmintic)!
 hsqk<kQk<K~{<c!)Stomachic)!
 K~g<G{qh<HPg<ogiz<zq!)Parasiticide)!
 uxm<sqbgx<xq!)Emollient)!
Chemical constituent 
 Phenolic compounds, are thymoquinone, dithymoquinone, 
thymohydroquinone and thymol. 
 Compounds are nigellin, tannin, resin, protein, reducing sugar, saponins, 
arabic acids. 
 Free amino acids present are cystine, lysine, aspartic acid, glutamic acid, 
alanine, tryptophan, valine, leucine. 
G{l<<<<!
! gVR<sQvgk<kie<!gvh<hoeiM!H{<[l<!
! uVR<sqvib<h<!hQfsL!lix<Xl<!.!nVf<kqeiz<!
! gib<s<sz<!kjzuzqBr<!g{<uzqBl<!OhiLzgqz<!
! uib<s<s!lVf<okeOu!ju/!
gvh<hie<?!H{<?!dm<$M?!kjzOfib<?!g{<O{ib<!-jugTl<?!sqvr<G?!
ubqx<Xh<ohiVlz<?!Ge<ll<?!liIH?!uzq?!-Vlz<?!uif<kq!Rg<gitl<?!uQg<gl<!
gilijz!NgqbjugTl<!gVR<sQvgk<kiz<!fQr<Gl</!
! !
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3/!giIOhigiqsq!
Botanical name : Psoralea corylifolia 
Family   : Fabaceae 
Parts used! ! ;! uqjk!
Sju!   : jgh<H  
ke<jl! ! ;! ouh<hl< 
hqiqU! ! ! ;! giIh<H!
osb<jg<<< !
 lzlqtg<gq!)Laxative) 
 ouh<hL{<mig<gq!)Stimulant) 
Chemical constituent 
 Psceralidin, bakuclicin, psaralin, angelicin, psoracurylifols A-E, 
prenylflavonoids, corylifols A and C. 
 Isobavachalcone, neobavaisoflavane, ispsoralen and psuralen. 
G{l<<<<!
! giIOhig!liliqsq!g{<mix<!gvh<hie<H{<!
! hQIsGu!fR<sqjuOhil<!hqk<kL{<mil<!.!hiIlQkqz<!
! uik!ghfjls<sz<!ue<osixqsqvr<GlXR<!
! sQk!lzi<g<Gpzib<!osh<H/!
-jkg<!gMue<?!uqv{l<?!si<h<huq]l<?!uiksqOz]<ll<?!kqeU?!bijes<osixq?!
gqvf<kq!-jugTg<G!dhObigqg<gzil</!-K!hsqjb!d{<mig<Gl</!!Gm<mk<jk!
uqzg<Gl</!!Neiz<!hqk<kk<jkh<!ohVg<Gl</!
!
! !
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4/!usl<H<<< !
Botanical name : Acorus calamus 
Family   : Acoraceae 
Parts used! ! ;! Oui<!
Sju!   : giIh<H!
ke<jl! ! ;! ouh<hl< 
hqiqU! ! ! ;! giIh<H!
osb<jg<<< ! ! !
 ouh<hL{<mig<gq!)Stimulant) 
 hsqk<kQk<K~{<c!)Stomachic) 
 Ljxouh<hgx<xq!)Antiperiodic) 
 ngm<Muib<ugx<xq!)Carminative) 
 Glm<mozPh<hq!)Nauseant) 
 uif<kqB{<mig<gq!)Emetic) 
 okix<Xh<HPugx<xq!)Disinfectant) 
 Fm<HPg<ogiz<zq!)!Germicide) 
 
Chemical constituents 
 Three new sesquiterpenes, 1 beta, 7, alpha(H)-cadinane-4 alpha, 6 alpha, 10 
alpha – tricol,(1), 1 alpha, 5 beta-gaaiane-10 alpha-0-ethyl-4beta, 6beta-diel(2) and 6 
beta, 7 beta(H)-cadinane-1 alpha, 4 alpha, 10alpha-triol(3) 
G{l<<<<!
! hil<hikq!fR<sx<!Hkh<H{<!uzquqmhigr<!Ge<ll<!
! $l<hi!iqvk<khqk<!kl<Lg!fix<xl<ue<!$jzse<eq!
! uql<hil<jh!gisl<!hqz<gR<!sqzqhkl<!uQxqVlz<!
! kil<hir<!gqVlq!bqjuObG!lisqu!sl<hqjeOb!
wz<zifR<Sgt<?!H{<ujggt<?!Jujguzq?!Ge<ll<?!-vk<k!hqk<kl<?!
uib<fix<xl<?!$jz?!Lh<hq{q?!-Vlz<?!=vz<!Ofib<gt<?!bijeg<giz<?!fimih<HP!
NgqbjuOhil</!
! !
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5/!Htqbl<!-jz<<< !
Botanical name : Tamarindus indica 
Family   : Caesalpinoideae 
Parts used! ! ;! -jz?!=Ig<G?!H,?!gib<?!YM?!ogim<jm?!hm<jm!
Sju!   : Htqh<H  
ke<jl! ! ;! ouh<hl< 
hqiqU! ! ! ;! giIh<H!
osb<jg<<< ! ! !
 ouh<hL{<mig<gq!)Stimulant) 
 Kui<h<hq!)Astringent) 
 dvlig<gq!)Tonic) 
Chemical constituents 
 Tannin, saponin, alkane-nonacosane-6-one anthracene and Dimeric 
procyanidin. 
G{l<<<<!
! nPH{<j{!fQg<Gl<!nmz<Osijh!lix<Xl<!
! wPhi{<M!juh<Ohig<Gl<!-h<hiz<!.!LPKl<!
! ntqbs<sq!uf<kg{<O{k!bix<Xr<!gezil<!
! Htqbqjzjb!fe<xib<h<!Hgz</!
H{<?!Osijh?!hi{<M?!g{<O{iBl<!Ohil</!!gez<!d{<mil</!
! !
 47
6/!wt<!w{<o{b<< < << < << < <!
Botanical name : Sesamum Indicum 
Family   : Pedaliaceae 
Parts used! ! ;! -jz?!H,?!gib<?!uqjk!
Sju!   : -eqh<H  
ke<jl! ! ;! ouh<hl< 
hqiqU! ! ! ;! -eqh<H!
osb<jg<<< ! ! !
 dvlig<gq!)Tonic) 
 sqXfQIh<ohVg<gq!)Diuretic) 
 lzlqtg<gq!)!Laxative) 
 ouh<hL{<mig<gq!)Stimulant) 
 
Chemical contituents 
 Unsaturated fatty acids, especially oleic and linoleic acids, palmitic and 
stearic.  5.7% moisture, 20% crude protein, 3.7 ash, 3.2 gude fiber, 54% fat and 13.4 
carbohydrates potassium, magnesium, calcium, sodium, phospherics. 
G{l<<<<!
! wt<T!lVf<jkg<!ogMg<Gl<!wxezif<!kq{<jlkVl<!
! dt<tqjzjbs<!Osi<g<Gl<!dkqvk<jkk<!.!kt<TlqV!
! g{<[g<!ogitqogiMg<Gr<!gisL{<mil<!hk<kLlil<!
! h{<[g<!gqmi<HiqBl<!hiI/!
uqjkjb!njvk<Kg<!ogikqg<gjuk<Kg<!gm<cgTg<Gg<!gm<m?!nju!
hg<GuhjmBl</!
! !
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7/!NMkQ{<mih<hijts<siQ < < <Q < < <Q < < < X!
Botanical name : Aristolochia bracteolata 
Family   : Aristolochiaceae 
Parts used! ! ;! -jz?!uqjk?!Oui<?!s&zl<!
Sju!   : jgh<H  
ke<jl! ! ;! ouh<hl<!
hqiqU! ! ! ;! giIh<H!
osb<jg<<< ! ! !
 HPg<ogiz<zq!)Anthelmintic) 
 $kgL{<mig<gq!)Emmenagogue) 
 ouh<hL{<mig<gq!)Stimulant) 
 dvlig<gq!)Tonic) 
 fQIlzl<Ohig<gq!)Purgative) 
 dmx<Oxx<xq!)Alterative) 
 Ljxouh<hgx<xq!)Antiperiodic) 
Chemical constituents 
 Aristolactams, aporphines, protoberberines, isoquinolines, benzyli 
soquinolinesnis, amides, flavonoids, lignans, biphenyl ethers, coumarins, tetralones, 
terpenoids, benzenoids, steroids and others. 
G{l<<<<!
! gqvf<kqgvh<!he<oug<jg!Ogsfzq!lif<jk!
! bvf<jk!uqjejb!bXg<Gl<!.!Kxf<K!
! hqiqobi{i!Ofib<gjtBl<!hqe<Le<!hivilz<!
! lxqB{i!&zqbjm!uib</!
gqvf<kq?!gvh<hie<?!lbqi<ogim<ch<Ohikz<?!g{R<$M!Ngqbux<jxh<!Ohig<Gl</!
! !
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8/!lqtG!
Botanical name : Piper nigrum 
Family   : Piperaceae 
Parts used  : uqjk?!ohic!
Sju! ! ! ;! jgh<H?!giIh<H!
ke<jl! ! ;! ouh<hl<!
hqiqU! ! ! ;! giIh<H!
osb<jg<<< !
 ngm<Muib<ugx<xq!)Carminative) 
 Ljxouh<hgx<xq! )Antiperiodic) 
 kch<H{<mig<gq!)Rubefacient) 
 ouh<hL{<mig<gq!)Stimulant) 
 uQg<gr<gjvs<sq!)Resolvent) 
 uiklmg<gq!)Antivatha) 
 fs<siq!)Antidote) 
Chemical constituents 
 Piperine, α-tocophenal, α-pinene, β-cargophyllene, β-pinene, β-eudesmal, 
limonene, Delta-3carene, sabinene, Eugenol, Terpenin-4-ol, Hedycaryal, 
caryophyllene oxide. 
 Phytochemicals includes amides, piperidines, pyrrolidines and trace amounts 
of safrale. 
 Also contains, lysine, hitidine and cystine. 
G{l<<<<!
! ntjuBxig<givl<!njmf<kqVg<Gl<!uik!
uqjtjuobz<!zilXg<Gl<!olb<Ob!–!lqtgqe<gib<!
! g{<mui<g<Gl<!-e<hlil<!giiqjgOb!–!sQp<&zr<!
! ogi{<mui<g<G!fe<lVf<kir<!%X/!
!
!! -K!utqOfib<gjtBl<!sQp<!&zk<jkBl<!fQg<Gl</!
! !
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9/!Nuivl<!Oui<h<hm<jm< < < << < < << < < < !
Botanical name : Cassia auriculata 
Family   : Caesalpinoideae 
Parts used  : Oui<?!-jz?!H,?!hm<jm!
Sju! ! ! ;! Kui<h<H!
ke<jl! ! ;! km<hl<!
hqiqU! ! ! ;! -eqh<H!
!
osb<jg<<< !
 dmx<Oxx<xq!(Alterative) 
 
Chemical constituents 
 Tartaric acid, acetic acid, succinic acid, gum, pectin, sugar, tannins, alkaloids, 
flavanoids, sesquiterpenes, glycosides (32-35), Phenolic Anti oxidants, Cardiac 
glycosides, ketoacids, xylose  (alpha-1,6) and galactose. 
 
G{l<<<<!
! Olgk<kqeiOz!uqjtf<kszl<!oum<jmbez<!
! Ngk<kqe<!H{<O{i!mVr<gqv{q!–!Ohigk<kie<!!
! Nuijvh<!hR<sr<ogit<!n^<kqSvf<!kigLl<!Ohil<!
Wuijvg<!g{<lmliOk!
!
!! -K!fQiqpqU?!oum<jm?!H{<?!gqvi{q?!!n^<kqSvl<?!kigLl<!fQg<Gl</!
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Fig. No. 4   INGREDIENTS OF KARAPPAN KUDINEER CHOORANAM 
INTERNAL 
 
osr<gk<kiiqh<hm<jm< < < << < < << < < < !
(Capparis sepiaria) 
lqtG!!
(Piper nigrum) 
sqe<eq!-jz<<< !
(Acalypha fruticosa) 
sqXGxqR<sie<!Oui<< < << < << < <!
(Gymnema sylvestre) 
 52
!Fig. No. 5  gvh<hie<!GcfQi<!< < Q << < Q << < Q < S,v{l<<<<!
  
!
gvh<hie<!GcfQi<!S,v{l<< < Q < << < Q < << < Q < <!
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!
! !
Fig. No. 6  INGREDIENTS OF KARAPPAN ENNAI 
EXTERNAL 
 
Htqbl<-jz<<< !
!)Tamarandus indica) 
Nuivl<Oui<h<hm<jm< < < << < < << < < < !!
)Casia auriculata) 
gVR<sQvgl<< Q << Q << Q <!
)Nigella sativa) 
lqtG!
)Piper nigrum) 
gii<Ohigiqsq<<< !
)Psoralea carylifolia) 
usl<H<<< !
)Acorus calamus) 
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!
!
!
!
!
!
Fig. No. 7 gvh<<<<hie<!w{<o{b< << << < << << 
wt<!w{<o{b<< < << < << < <!
)Seasamum indicum) 
NMkQ{<mihijtQ <Q <Q < !
)Aristolochia bracteolata) 
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6. BIO-CHEMICAL ANALYSIS OF  KARAPPAN KUDINEER CHOORANAM 
 
Preparation of the extract:   
   5gms of the drug was weighed accurately and placed in a 250 ml clean 
beaker.  Then 50ml of distilled water is added and dissolved well.  Then it is boiled 
well for about 10 minutes.  It is cooled and filtered in a 100ml volumetric flask and 
then it is make up to 100ml with distilled water.  This fluid is taken for analysis. 
QUALITATIVE ANALYSIS 
S.NO EXPERIMENT OBSERVATION INFERENCE 
1.  TEST FOR CALCIUM 
2ml of the above prepared extract is taken 
in a clean test tube. To this add 2ml of 4% 
Ammonium oxalate solution 
A white precepitate 
is formed 
Indicates the 
presence of 
calcium 
2. TEST FOR SULPHATE 
2ml of the extract is added to 5% Barium 
chloride solution. 
A white precipitate is 
formed 
Indicates the 
presence of 
sulphate 
3.  TEST FOR CHLORIDE 
The extract is treated with silver nitrate 
solution 
No white precipitate 
is formed 
Absence of 
chloride 
4. TEST FOR CARBONATE 
The substance is treated with 
concentrated Hcl. 
No Brisk 
effervessence is 
formed 
Absence of 
carbonate 
5. TEST FOR STARCH 
The extract is added with weak iodine 
solution 
Blue colour is 
formed 
Indicates the 
presence  of  
starch 
6.  TEST FOR FERRIC IRON 
The extract is acidified with Glacial 
acetic acid and potassium ferro cyanide. 
No blue colour is 
formed 
Absence of 
Ferric iron 
7. TEST OF FERROUS IRON  
The extract is treated with concentrated 
Nitric acid and Ammonium thio cynate 
solution 
No blood red colour 
is formed 
Absence  of 
ferrous Iron. 
8.  TEST FOR PHOSPHATE No yellow Absence of 
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The extract is treated with ammonium 
Molybdate and concentrated nitric acid 
precipitate is formed phosphate 
9.  TEST FOR ALBUMIN 
The extract is treated with Esbatch’s 
reagent 
No Yellow 
precipitate is formed 
Absence of 
Albumin 
10.  TEST FOR TANNIC ACID 
The extract is treated with ferric 
choloride. 
No Blue black 
precipitate is formed 
Absence of 
Tannic acid 
11.  
TEST FOR UNSATURATION 
Potassium permanganate solution is 
added to the extract 
It gets decolourised. 
Indicates the 
presence of   
unsaturated 
compound 
12.  TEST FOR THE REDUCING SUGAR 
5ml of Benedict’s qualitative solution is 
taken in a test tube and allowed to boil for 
2 mins and add 8-10 drops of the extract 
and again boil it for 2 mins. 
No Colour change 
occurs. 
Absence of 
Reducing sugar 
13.  TEST FOR AMINO ACID 
One or two drops of the extract is placed 
on a filter paper and dried well. After 
drying, 1% Ninhydrin is sprayed over the 
same and dried well. 
Violet colour is 
formed 
Indicates the 
presence of 
Amino acid 
14. TEST FOR ZINC 
The extract is treated with Potassium 
Ferrocyanide. 
No white precipitate 
is formed 
Absence of Zinc. 
 
Inference: 
  The extract prepared from the given sample KARAPPAN KUDINEER 
CHOORANAM  contains calcium, sulphate, starch,  unsaturated compound and 
amino acid, Biochemical Analysis report was given by Mrs. N.Nagaprema, M.Sc., 
M.Phil., Head of the Department, Biochemical Department, Government Siddha 
Medical College, Palayamkottai. 
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7. PHARMACOLOGICAL ANALYSIS 
ANTI-INFLAMMATORY ACTIVITY OF KARAPPAN KUDINEER 
CHOORANAM 
  The anti-inflammatory activities of karappan kudineer chooranam at 100 
mg/kg and 200mg/kg doses were evaluated using carrageenan-induced paw edema 
method. The inflammation was readily produced in the form of edema with the help 
of irritant such as carrageenan. Carrageenan is a sulphated polysaccharide obtained 
from sea weed (Rhodophyceae) and when injected cause the release of prostaglandins 
by the way it produces inflammation and edema. 
REQUIREMENTS: 
Animal                        : Albino rat (180-200 g) 
Drugs and chemicals     :  Carrageenan (1%w/v),  
Diclofenac sodium (standard), 
Carboxy methyl cellulose (1%w/v), 
Plethysmo meter. 
Test compound                :  karappan kudineer chooranam 
 
METHOD: 
  Anti-inflammatory activity was performed by the following procedure of 
Bhandri et al(1)The animals were divided into 4 groups each having six animals. A 
freshly prepared suspension of carrageenan (1% w/v , 0.1 ml) was injected to the 
planter region of left hind paw of each rat. One group was kept as control and the 
animals of the other groups were pretreated with the KARAPPAN KUDINEER 
CHOORANAM test Compounds dissolved with 2 ml sterile water given through 
orally 30 min before the carrageenan treatment. The paw volumes of the test 
compounds, standard and control groups were measured at 60,240,360 minutes of 
carrageenan treatment with the help of  plethysmometer . Mean increase in paw 
volume was measured and the percentage of inhibition was calculated. 
% Anti-inflammatory activity = (Vc-Vt / Vc) x 100 
  Where, 
 Vt-mean increase in paw volume in rats treated with test compounds, 
Vc-mean increase in paw volume in control group of rats. 
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TABLE No.1 
ANTI-INFLAMMATORY ACTIVITY OF KARAPPAN KUDINEER 
CHOORANAM 
Treatment Dose (mg/kg) 
Paw volume(ml) as 
measured by mercury 
displacement at 6 hour 
Percentage 
inhibition of 
paw edema 
Group I  Normal saline 10ml/kg orally 6.10±0.96 - 
Group II Std 
10mg/kg 
I.P.Diclofenac 
sodium 
2.60±0.40 57.37%*a 
Group III   KKC 100/kg.Orally. 2.96±0.48 51.47%*a 
Group IV   KKC 200mg/kg.Orally. 2.80±0.52 54.09%*a 
* Data are expressed as Mean ± S.E.M. 
*Data were analyzed by one way ANOVA followed by Newman’s keul’s multiple 
range tests, to determine the significance of the difference between the control group 
and rats treated with the test compounds. 
*a   Values were significantly different from normal control at P< 0.01. 
Results 
  Anti- inflammatory activity 
  Both extracts of KARAPPAN KUDINEER CHOORANAM at doses 
100mg/kg and 200mg/kgwere tested for their Anti- inflammatory activity by using 
carrageenan Induced rat paw edema method and the results are tabulated in table no 1.  
The results reveals that   both extracts of KARAPPAN KUDINEER CHOORANAM  
at 100mg/kg and 200mg/kg doses possesses significant Anti- inflammatory activity 
when compared to control group at p<0.01. 
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ANTI HISTAMINE ACTIVITY  KARAPPAN KUDINEER CHOORANAM 
Experimental Animals 
  Wister rats (175-200 g) of either sex housed in standard conditions of 
temperature (22 ± 2°C), relative humidity (55 ± 5%) and light (12 hrs light/dark 
cycles) were used. They were fed with standard pellet diet and water ad libitum. The 
experimental protocol was approved by Institutional Animal Ethical Committee as per 
the guidance of CPCSEA,  
  Histamine and acetylcholine induced bronchospasm in rats of either sex were 
divided into two groups of six animals each and exposed to 0.1% w/v of histamine 
dihydrochloride aerosol in histamine chamber. The progressive dyspnea was observed 
in animals when exposed to histamine aerosol. The end point, preconvulsion dyspnea 
(PCD) was determined from the time of aerosol exposure to the onset of dyspnoea 
leading to the appearance of convulsion. As soon as PCD commenced, the animals 
were removed from chamber and placed in fresh air. PCD of this time was taken as 
day 0 value. Both groups of rats were given ethanolic extract of drugs at the dose of 
100 mg/kg, and 200 mg/kg, p.o. respectively, once a day for 7 days. On the 7 day 2 h 
after the last dose, the time for the onset of PCD was recorded as on day 0. Same 
procedure was followed in another set of animals (n = 6) for acetylcholine induce 
bronchospasm study using 0.5% acetylcholine chloride. The percentage increased in 
time of PCD was calculated using following formula. 
Percentage increased in time of PCD = (1-T1/T2) × 100 
where T = time for PCD onset on day 0, T = time for PCD onset on day 7 
PRECONVULSIVE DYSPNEA (SEC) 
Treated 
group 
histamine – induced 
bronchospasm 
Acetylcholine - induced 
Bronchospasm 
 
KKC 
Before 
treatment 
(control) 
After 
treatment 
% 
increase 
Before 
treatment 
(control) 
After 
treatment 
% 
increase 
200 
mg/kg, 
p.o 
 
105.60 ± 2.30 
282.42 ± 
3.11* 
 
62.60 
 
145.06 ± 1.12 
202.20 ± 
2.06* 
 
28.25 
400 
mg/kg, 
p.o 
 
115.01 ± 1.88 
530.01 ± 
4.52* 
 
78.30 
 
136.02 ± 0.20 
252.02 ± 
3.06* 
 
46.06 
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Mast Cell Degranulation Studies. 
HISTAMINE -INDUCED MAST CELL DEGRANULATION IN GUINEA PIG: 
Procedure: 
Guinea pig were divided in four groups, (n=5). The seven days drug treatment 
schedule was followed. 
  Group-I received Distilled water (10 ml /kg p.o.)  
  Group-II was treated with sodium cromoglycate (0.5mg/kg, intraperitonialy).  
  Groups-III was treated with kk (200mg/kg), p.o 
  Groups- IV were treated with kk (400 mg/kg, p.o) respectively 
  On 7 th day, 2 hours after the assigned treatment mast cells were collected 
from the peritoneal cavity (Lakashmana et al, 2001, Lakadawala et al 1980).The 
guinea pig were anesthetized with ether and were injected 10 ml of normal saline 
solution into peritoneal cavity. The abdomen was gently massaged for 90 seconds. 
The peritoneal cavity was carefully opened and the fluid containing mast cells were 
aspirated and collected in siliconised test tube containing 7 to 10 ml of RPMI-1640 
Medium (pH 7.2- 7.4). The mast cells were then washed three times by centrifugation 
at low speed (400-500 rpm) and the pallet of mast cells was taken from the medium. 
Then 1% solution of arachodonic acid was added to the mast cell suspension 
(approximately 1 x 10 6 /ml) and incubated at 37ºC in a water bath for 10 min. Later 
they were stained with 1 % Toludine blue (Dye) and observed under high power 
microscope field (400 X). A total 100 cells were counted from different visual areas 
and percent protection against - induced mast cell degranulation was calculated 
MAST CELL PERCENTAGE 
Group Treatment Intact Disrupted % Protection 
1 Distilled water (10 
ml/kg, p.o) 
23.7 ± 0.45 86.3 ± 0.45 - 
 
2 
Sodium cromoglycate 
(0.5mg/kg, i.p) 
 
73.20 ± 6.25** 
 
26.80 ± 6.25** 
 
86.03 
3 kk – (200mg/kg, p.o) 49.02 ± 0.23** 50.98 ± 0.23** 50.71 
4 kk– (400 
mg/kg, p.o) 
40.05 ± 50.01** 59.95 ± 50.01** 59.68 
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ACUTE ANTI-INFLAMMATORY STUDY ON KARAPPAN ENNAI 
(Externally) 
 
BY HINDPAW METHOD IN ALBINO RATS 
Procedure: 
  Anti-inflammatory study of karappan ennai was studied in healthy albino rats. 
Six rats were selected and divided in to three groups. To the first group distilled water 
was given and kept as control. The second group was given the standard drug 
diclofenacat a dose of 5 mg/kg body weight. The third group was treat with the test 
drug extermelly.Before the application of the drug the kind paw volume of all rats 
was measure .This was done by dipping the kind paw upto the tibio dorsal junction in 
a mercury plethysmography. Subcutaneous injection of 0.1 ml of 1%w/v carrageenin 
in water was made in to planter surface of both the kind paw of each rat. Three hours 
after injection the kind paw volume was measured once again. The difference 
between the initial and final volume would show the amount of inflammation. 
  Taking the volume in the control group as 100% of inflammation the 
inflammatory or anti-inflammatory effect of the test group is calculated, injection of 
0.1 ml of 1%w/v of carrageenin in water was made into planter surface of both the 
hind paw if each rat. 
  Three hours after carrageenin injection, the hind paw volume was measured 
once again. Difference between the initial and final value were noted and compared. 
  The method is more suitable for studying anti-inflammatory activity on acute 
inflammation. 
  The result of the drug is compared with the standard as well as control group. 
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 Study of Acute –Inflammatory By Hind Paw Method 
Serial 
no 
Name of 
drugs/groups 
Dose/100 
gram 
body 
weight 
Initial 
reading 
average 
final 
reading 
average 
Mean 
difference 
Percentage 
inflammation 
Percentage 
inhibition 
remarks 
1 Water 2 ml 0.9 1.8 - 100 -  
2 Diclofenac 5 mg/kg 0.9 1.2 0.3 25 75  
3 Karappanennai 200mg/kg 1.2 1.6 0.4 25 75  
 
 
 
  
100
25
37.5
0
75 75
0
20
40
60
80
100
120
Water Diclofenac Karappanennai
Percentage inflammation
Percentage inhibition
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TOXICITY STUDIES 
EVALUATION OF ACUTE TOXICITY STUDY OF KARAPPAN 
KUDINEER CHOORANAM 
Effect of Acute Toxicity Study (14 Days) of KARAPPAN KUDINEER 
CHOORANAM 
Table no –12   Physical and behavioral examinations. 
Group no. Dose(mg/kg) Observation sign No. of animal affected. 
Group-I 5mg/kg Normal 0 of 3 
Group- II 50mg/kg Normal 0 of 3 
Group-III 300mg/kg Normal 0 of 3 
Group-IV 1000mg/kg Normal 0 of 3 
Group-V 2000mg/kg Normal 0 of 3 
Table no-13    Home cage activity 
Functional 
and 
Behavioural 
observation 
Observati
on 
5 
mg/kg 
Group 
(G-I) 
50 
mg/kg 
(G-II) 
300 
mg/kg 
(G-III) 
1000 
mg/kg 
(G-IV) 
2000 
mg/kg 
(G-V) 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Body 
position Normal 3 3 3 3 3 
Respiration Normal 3 3 3 3 3 
Clonic 
involuntary 
Movement 
Normal 3 3 3 3 3 
Tonic 
involuntary 
Movement 
Normal 3 3 3 3 3 
Palpebral 
closure Normal 3 3 3 3 3 
Approach 
response Normal 3 3 3 3 3 
Touch 
response Normal 3 3 3 3 3 
Pinna reflex Normal 3 3 3 3 3 
Tail pinch 
response Normal 3 3 3 3 3 
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Table no-14  Hand  held  observation 
Functional 
and 
Behavioral 
observation 
Observation 
Control 
5 mg/ 
kg 
(G-I) 
50 
mg/kg 
(G-II) 
300mg/
kg 
(G-III) 
1000mg/
kg 
(G-IV) 
2000mg/
kg 
(G-V) 
Female 
n=3 
Femal
e n=3 
Femal
e n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Reactivity Normal 3 3 3 3 3 3 
Handling Normal 3 3 3 3 3 3 
Palpebral 
closure 
Normal 3 3 3 3 3 3 
Lacrimation Normal 3 3 3 3 3 3 
Salivation Normal 3 3 3 3 3 3 
Piloerection Normal 3 3 3 3 3 3 
Pupillary 
reflex 
Normal 3 3 3 3 3 3 
Abdominal 
tone 
Normal 3 3 3 3 3 3 
Limb tone Normal 3 3 3 3 3 3 
 
Table no-15   Mortality 
Group no Dose no(mg/kg) Mortality 
Group-I 5(mg/kg) 0 of 3 
Group-II 50(mg/kg) 0 of 3 
Group-III 300(mg/kg) 0 of 3 
Group-IV 1000(mg/kg) 0 of 3 
Group-V 2000(mg/kg) 0 of 3 
 
RESULT: 
  From acute toxicity study it was observed that the administration of 
KARAPPAN KUDINEER CHOORANAM at a dose of 2000 mg/kg to the rats do not 
produce drug-related toxicity and mortality. So No-Observed-Adverse-Effect- 
Level (NOAEL) of KARAPPAN KUDINEER CHOORANAM is 2000 mg/kg. 
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DISCUSSION 
  KARAPPAN KUDINEER CHOORANAM was administered single time at 
the dose of 5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats and 
observed for consecutive 14 days after administration. Doses were selected based 
on the pilot study and literature review. All animals were observed daily once for 
any abnormal clinical signs. Weekly body weight and food consumption were 
recorded. No mortality was observed during the entire period of the study. Data 
obtained in this study indicated no significance physical and behavioural signs of 
any toxicity due to administration of KARAPPAN KUDINEER CHOORANAMat 
the doses of 5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats.  
  At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand 
held activity were observed. Home cage activities like Body position, Respiration, 
Clonic involuntary movement, Tonic involuntary movement, Palpebral closure, 
Approach response, Touch response, Pinna reflex, Sound responses, Tail pinch 
response were observed. Handheld activities like Reactivity, Handling, Palpebral 
closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominaltone, 
Limb tone were observed. Functional and behavioral examination was normal in all 
treated groups.Food consumption of all treated animals was found normal as 
compared to normal group. 
  Body weight at weekly interval was measured to find out the effect of 
KARAPPAN KUDINEER CHOORANAM on the growth rate. Body weight 
change in drug treated animals was found normal. 
 
INTERPRETATION: 
 
 KARAPPAN KUDINEER CHOORANAM was administered single time at 
the dose of 5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats and 
observed for consecutive 14 days after administration. Doses were selected based 
on the pilot study and literature review. All animals were observed daily once for 
any abnormal clinical signs. Weekly body weight and food consumption were 
recorded. No mortality was observed during the entire period of the study. Data 
obtained in this study indicated no significance physical and behaviou ral signs of 
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any toxicity due to administration of KARAPPAN KUDINEER CHOORANAM at 
the doses of 5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats.  
At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand 
held activity were observed. Home cage activities like Body position, Respiration, 
Clonic involuntary movement, Tonic involuntary movement, Palpebral closure, 
Approach response, Touch response, Pinna reflex, Sound responses, Tail pinch 
response were observed. Handheld activities like Reactivity, Handling, Palpebral 
closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominaltone, 
Limb tone were observed. Functional and behavioral examination was normal in all 
treated groups.Food consumption of all treated animals was found normal as 
compared to normalgroup. 
  Body weight at weekly interval was measured to find out the effect of 
KARAPPAN KUDINEER CHOORANAMon the growth rate. Body weight change 
in drug treated animals was found normal. 
  
 67
SUB-ACUTE TOXICITY STUDY IN WISTAR RATS TO EVALUATE 
TOXICITY PROFILE OF KARAPPAN KUDINEER CHOORANAM 
 
Table :16 EFFECT OF SUB- ACUTE DOSE (28 DAYS)OF KARAPPAN 
KUDINEER CHOORANAM ON BODY WEIGHT IN GRAM 
 
GROUP CONTROL LOW MID HIGH 
1st day 121.3±1.03 124±1.543 123.3±2.231 125.3±2.23 
7th day 131.3±1.03 130.3±1.343 130±2.113 136±2.11 
14th day 133.1±1.004 101.3±1.12 101.4±2.012 102.4±2.012 
21st day 102.3±2.120 109.2±1.501 103±1.131 104±1.13 
28th day 112.3±1.041 111.3±1.202 142±2.0405 145±2.040 
 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one 
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group. 
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EFFECT OF SUBACUTE DOSE (28 DAYS)OF KARAPPAN KUDINEER 
CHOORANAM ON ORGAN WEIGHT (PHYSICAL PARAMETER)                      
IN GRAM 
GROUP CONTROL LOW MID HIGH 
HEART 0.33±0.02 0.44±0.04 0.61±0.11 0.51±0.02 
LIVER 2.21± 0.23 1.23±0.23 1.20±0.01 1.13± 0.23 
LUNGS 1.21±0.10 0.91±0.14 0.40±0.24 1.33±0.10 
KIDNEY L 0.33±0.02 1.42±0.03 0.33±0.02 0.31±0.02 
 R 0.51±0.024 1.04±0.02 0.31±0.024 0.32±0.024 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one 
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group.  
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EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF KARAPPAN KUDINEER 
CHOORANAM ON HAEMATOLOGICAL PARAMETERS 
 
Drug 
treatment 
RBC 
million 
cells/cm
m 
WBC  
cells/cmm 
Haemoglo
bin gm % 
Differenial count% 
Neutro 
phils 
Eosino 
phils 
Mono 
cyte 
Limpo 
cyte 
Control 5.21±0.
40 
7251.41±
23.32 
13.40±0.4
5 
30.27±1.
20 
3.53±0.
11 
2.45±0.
15 
22.13±3.
32 
LOW  4.47±0.
20 
5333.04±
23.22 
12.20±0.4
3 
24.54±1.
41 
1.10±0.
14 
3.12±0.
30 
22.22±3.
51 
MID 5.33±0.
21 
5303.25±
32.35 
13.11±1.0
3 
29.32±2.
22 
.44±0.1
2 
2.32±0.
40 
22.13±3.
32 
HIGH 5.26±0.
21 
6487.25±
32.35 
15.11±1.0
3 
27.32±2.
22 
0.50±0.
12 
2.34±0.
40 
23.13±3.
32 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one 
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group.  
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Table :19  EFFECT OF SUB- ACUTE DOSE(28 DAYS)OF KARAPPAN 
KUDINEER CHOORANAM ON BIOCHEMICAL PARAMETERS 
 
Drug 
Treatment 
SGPT 
(IU/L) 
SGOT 
(IU/L) 
ALP 
(IU/L) 
Urea 
(mg/dl) 
Creatinine 
(mg/dl) 
Control 41.14±3.02 12.24±4.31 242.12±11.32 34.35±3.00 0.84±0.03 
LOW 41.13±3.22 10.23±4.01 250.11±12.42 39.53±2.42 0.40±0.04 
MID 39.21±4.44 13.31±2.21 244.45±4.14 38.12±2.22 0.75±0.04 
HIGH 41.21±4.44 11.31±2.21 233.45±4.14 39.12±2.22 0.86±0.04 
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EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF KARAPPAN KUDINEER 
CHOORANAM BIOCHEMICAL PARAMETERS 
 
GROUP CONTROL KKC 
(200mg/kg) 
KKC 
(400mg/kg) 
KKC 
(600mg/kg) 
TOTAL 
BILIRUBIN 
(mg/dl) 
1.308±0.2457 0.987±0.27 0.891±0.76 0.110±0.19 
  
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group.  
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Table:21 EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF KARAPPAN 
KUDINEER CHOORANAM ON FOOD INTAKE IN GRAM 
 
GROUP CONTROL low mid High 
1st DAY 17.33±13.5110 18.1672±14.3 11.10±21.71 16.5±7.62 
7th DAY 14.5±11. 09.863±12.67 15.73±9.853 10.17±14.41 
14th DAY 17.83±8.72 09.83±14.28 09±13.96 18.72±8.981 
21st DAY 10.87±12.4 14±8.466 14.88±9.43 18.17±8.02 
28th DAY 11.10±11.38 17.38±11.50 09±8.90 09±7.57 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group 
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Table:22. Effect of Sub- Acute Dose (28 Days) Of  KARAPPAN KUDINEER 
CHOORANAM On Water Intake in ml 
GROUP CONTROL KCC (200mg/kg) 
KKC 
(400mg/kg) 
KKC 
(600mg/kg) 
1st DAY 88.38±12.110 78.12±1.26 101.0±11.99 65.5±7.03 
7th DAY 75.4±10.738 89.63±10.770 70.63±9.863 79.67±3.50 
14th DAY 48.3±7.17 79.63±13.12 79±13.96 89.12±8.981 
21st DAY 81.67±11.49 65±0.462 55.88±9.550 75.17±8.62 
28th DAY 72.0±10.40 73.48±10.04 76±8.61 60±7.53 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group 
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Table: 23  EFFECT OF SUB ACUTE DOSES (28 DAY) OF KARAPPAN 
KUDINEER CHOORANAM ON ELECTROLYTES: - 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); NS- non-significant, *p<0.05, 
**p<0.01, ***p<0.001,  
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GROUP CONTROL 
KKC 
(200mg/kg) 
KKC 
(400mg/kg) 
KKC 
(600mg/kg) 
Sodium (mg/dl) 153.90±0.55 144.00±0.92 150±0.71 161.00±0.60 
Calcium(mg/dl) 11.280±0.19 13.00±0.183*** 14.2±0.19*** 16.10±0.11*** 
Phosphorus (U/L) 8.203±0.017 7.30±0.015ns 8.50±0.91ns 84.937±0.32* 
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6.0 RESULTS: 
CLINICAL SIGNS: 
  All animals in this study were free of toxic clinical signs throughout the 
dosing   period of 28 days. 
 Mortality: 
  All animals in control and in all the treated dose groups survived throughout 
the dosing period of 28 days. 
 Body weight: 
  Results of body weight determination of animals from control and different 
dose groups exhibited comparable body weight gain throughout the dosing period 
of 28 days. 
Food consumption: 
  During dosing and the post-dosing recovery period, the quantity of food 
consumed by animals from different dose groups was found to be comparable with 
that by control animals. 
Organ Weight: 
  Group Mean Relative Organ Weights (% of body weight) are recorded in 
Table No.22 Comparison of organ weights of treated animals with respective 
control animals on day 29 was found to be comparable similarly. 
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Hematological investigations: 
  The results of hematological investigations conducted on day 29 revealed 
following significant changes in the values of different parameters investigated 
when compared with those of respective controls; however, the increase or 
decrease in the values obtained was within normal biological and laboratory limits 
or the effect was not dose dependent. 
Biochemical Investigations: 
  Results of Biochemical investigations conducted on the day 29th and 
recorded in Table no 24, 25 revealed the following significant changes in the values 
of hepatic serum enzymes studied. When compared with those of respective 
control. However, the increase or decrease in the values obtained was within 
normal biological and laboratory limits. 
 
INTERPRETATION: 
1) All the animals from control and all the treated dose groups up to 15ml/kg 
survived throughout the dosing period of 28 days. 
2) No signs of toxicity were observed in animals from different dose groups 
during the dosing period of 28 days. 
3) Animals from all the treated dose groups exhibited comparable body 
weight gain with that of controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be 
comparable throughout the dosing period of 28 days 
5) Haematological analysis conducted at the end of the dosing period on day 
29th, revealed no abnormalities attributable to the treatment. 
6) Biochemical analysis conducted at the end of the dosing period on day 29th, 
no abnormalities attributable to the treatment. 
7) Organ weight data of animals sacrificed at the end of the dosing period was 
found to be comparable with that of respective controls. 
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DERMAL TOXICITY STUDIES 
EVALUATION OF ACUTE TOXICITY STUDY OF KE 
TEST METHOD 
  Preparation of the test item The test item was applied as such onto the skin 
of rats. Test item was prepared under dark conditions. Test Procedure A range 
finding study using a male and a female rat at dose 2000 mg/Kg b.w. was carried 
out in order to establish the dose levels for the main study. Approximately, 24 
hours before the treatment, around 10% dorsal skin area of each rat was clipped 
free of hair, without any abrasion. The appropriate amount of the test item was 
applied uniformly over the clipped area of each rat. After the application, the test 
item was held in contact with the skin for a period of 24 hours, using a porous 
gauze dressing (Modern Health Care, B. No.: 141, Expiry: October 2017) and 
bandaged with non-irritating adhesive tape. After 24 hours, the residual test item 
was wiped gently from the skin using wet cotton, soaked in water. Neck collar was 
used to prevent the ingestion of the test item from the application site. No mortality 
was observed for 4 days in the range finding study at 2000 mg/Kg b.w. Based on 
the results from the range finding experiment, limit test was chosen. In the limit 
test, 3 male and 3 female rats were exposed to 2000 mg/Kg b.w. 
 
Effect of Acute Toxicity Study (14 Days) of KE 
Table no-1   Mortality 
Group no Dose no(mg/kg) Mortality 
Group-I 5(mg/kg) 0 of 3 
Group-II 50(mg/kg) 0 of 3 
Group-III 300(mg/kg) 0 of 3 
Group-IV 1000(mg/kg) 0 of 3 
Group-V 2000(mg/kg) 0 of 3 
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Table :2 EFFECT OF SUB- ACUTE DOSE (28 DAYS)OF KARAPPAN 
ENNAI ON BODY WEIGHT IN GRAM 
GROUP CONTROL LOW MID HIGH 
1st day 131.3±1.03 134±1.543 133.3±2.231 135.3±2.23 
7th day 132.3±1.03 130.3±1.343 130±2.113 136±2.11 
14th day 133.1±1.004 101.3±1.12 101.4±2.012 102.4±2.012 
21st day 132.3±2.120 139.2±1.501 133±1.131 134±1.13 
28th day 132.3±1.041 131.3±1.202 122±2.0405 125±2.040 
 
 
Table no-1 
SKIN 
REACTION 
Observa
tion 
Control 
5 
mg/ kg 
(G-I) 
50 
mg/kg 
(G-II) 
300 
mg/kg 
(G-III) 
1000 
mg/kg 
(G-IV) 
2000 
mg/kg 
(G-V) 
Female 
n=3 
Female 
n=3 
Femal
e n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Erythea Normal - - - - - - 
Edema Normal - - - - - - 
Scaling    of 
epidermis Normal - - - - - - 
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DISCUSSION 
  KARAPPAN ENNAI  was administered single time at the dose of 5mg/kg, 
50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats and observed for 
consecutive 14 days after administration. Doses were selected based on the pilot 
study and literature review. All animals were observed daily once for any abnormal 
clinical signs. Weekly body weight and food consumption were recorded. No 
mortality was observed during the entire period of the study.  
  Body weight at weekly interval was measured to find out the effect of  
KARAPPAN ENNAI on the growth rate. Body weight change in drug treated 
animals was found normal. 
 
6.0 RESULTS: 
CLINICAL SIGNS: 
  All animals in this study were free of toxic clinical signs throughout the 
dosing   period of 28 days. 
 Mortality: 
  All animals in control and in all the treated dose groups survived throughout 
the dosing period of 28 days. 
 Body weight: 
  Results of body weight determination of animals from control and different 
dose groups exhibited comparable body weight gain throughout the dosing period 
of 28 days. 
 
INTERPRETATION: 
1) All the animals from control and all the treated dose groups up to 15ml/kg 
survived throughout the dosing period of 28 days. 
2) No signs of toxicity were observed in animals from different dose groups 
during the dosing period of 28 days. 
3) Animals from all the treated dose groups exhibited comparable body weight 
gain with that of controls throughout the dosing period of 28 days. 
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8. ANTIMICROBIAL STUDIES 
Aim 
 To study the Anti-microbial action of “Karappan Kudineer 
Chooranam ” against  Staphylococcus and Pseudomonas aeruginosa. 
 
Medium 
Mueller Hinton agar. 
 
Components of medium  
Beef extract   - 300gms/lit 
Agar    - 17 gms/lit 
Starch    - 1.5 gms/lit 
Casein Hydroxylate  - 17.5 gms/lit 
Distilled water  - 1000 ml 
PH    - 7.6 
 
Procedure 
 The media was prepared from the above components and poured and 
dried on a petri dish. The organism was streaked on the medium and the test 
drug (1gm drug in 10ml of water) was placed on the medium. This is incubated 
at 37°C for one over night and observed for the susceptibility shown up 
clearance around the drug. 
 
Result: 
  The test drug Karappan Kudineer Chooranam was moderately 
sensitive against Staphylococcus aureus and Pseudomonas aeruginosa 
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Fig. No. 8 
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9. OBSERVATIONS AND RESULTS 
 
Results were observe with respect to the following criteria 
1. Age 
2. Sex 
3. Religion 
4. Economic status of the patient 
5. Etiology 
6. Diet  
7. Paruvakaalam 
8. Distribution of land 
9. Mode of onset 
10. Clinical features of Sattai Karappan during admission 
11. Tridosha theory 
12. Ezhu udarkattugal 
13. Envagai thervugal  
14. Neerkuri, Neikuri 
15. Out-patient record 
16. In-patient case sheet reports 
17. Laboratory Investigations 
18. Results after treatment 
19. Results accoding to age criteria after treatment  
 
  20 Out patients and 20 In-patients were selected for this observational 
study 
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Table. No 1. AGE REFERENCE 
 
S.No. Age Number of cases 
(Out of 40) 
Percentage (%) 
1 3 – 7 years 12 47.5 
2 7 – 12 years 28 52.5 
 
 
 
Inference 
 The percentage was highest in the age group of 7 – 12 years, the 
percentage was 52.5 %, between the age of  3 – 7 years, the percentage was  
47.5%. 
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Table. No 2. SEX REFERENCE 
 
S.No. Sex Number of cases 
(Out of 40) 
Percentage (%) 
1 Male Children 12 30 
2 Female Children 28 70 
 
 
 
Inference: 
 Out of the 40 patients, 30 were Male children and 70 were Female 
children. 
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Table. No 3. RELIGION REFERENCE 
 
S.No. Religion Number of cases 
(Out of 40) 
Percentage (%) 
1. Hindu 37 92.5 
2. Christian 1 2.5 
3. Muslim 2 5 
 
 
 
Inference: 
 In 40 of cases, 92.5% of cases were Hindu, 2.5 % were Christian, 5% 
were Muslim. 
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Table. No 4. SOCIO ECONOMIC STATUS  
 
 
 
 
Inference: 
 Out of 40 patients, 70% of cases were Lower,  17.5% of cases were 
Middle and 12.5% of cases were Rich 
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S.No. Socio economic status 
Number of cases 
(Out of 40) 
Percentage (%) 
1 Lower income groups 28 70 
2 Middle income groups 7 17.5 
3. High income groups 5 12.5 
 90
 
Table. No 5. ETIOLOGY REFERENCE   
 
S.No. Etiology 
Number of cases 
(Out of 40) 
Percentage (%) 
1 Contact Allergens - - 
2 Positive family history 10 25 
3 Others (Diet, Climate, 
Debility) and Unknown 
30 75 
 
 
 
Inference : 
  Out of 40 patients Positive family was seen in 25% of cases, Others was 
seen in  75% of cases. 
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Table. No 6. DIET REFERENCE 
 
 
 
 
Inference: 
 
 Out of 40 patients 12.5% of cases were Vegetarian diet and 87.5% of 
cases were Mixed diet 
 
 
12.5
87.5
0
10
20
30
40
50
60
70
80
90
100
Vegetarian Mixed diet
Pe
rc
e
n
ta
ge
 
(%
)
Cases
S.No. Diet habit Number of cases 
(Out of 40) 
Percentage (%) 
1 Vegetarian 5 12.5 
2 Mixed diet 35 87.5 
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Table. No 7. PARUVAKAALAM 
S.No. Paruvakaalam Number of cases 
(Out of 40) 
Percentage (%) 
1. 
Kaarkaalam 
(Aavani & Purataasi) 
11 27.5 
2. 
Koothirkaalam 
(Ayppasi & Kaarthigai) 
7 17.5 
3. 
Munpanikaalam 
(Maarkazhi & Thai) 
14 35 
4. 
Pinpanikaalam 
(Maasi & Panguni) 
3 7.5 
5. 
Elavenilkaalam 
(Chithirai & Vaikaasi) 
0 0 
6. 
Muthuvenilkaalam 
(Aavani & Aadi) 
5 12.5 
 
 
Inference : 
 According to Paruvakaalam high incidence of 35 % of cases in 
Munpanikalam 27.5% of cases in Kaarkaalam , 17.5 cases in Koothir Kaalam, 
12.5% cases in Muthuvenil kaalam and 7.5 cases in Pinpani kaalam. 
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Table. No 8. DISTRIBUTION OF LAND 
 
 
 
 
Inference: 
 Out of 40 patients, 95% of cases belongs to Marutham and 5% of cases 
belongs to Neithal. 
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S.No. Thinai 
Number of cases 
(Out of 40) Percentage 
1 Kurinji (Hill) - - 
2 Mullai (Forest) - - 
3 Marutham (Fertile) 38 95 
4 Neithal (Coastal) 2 5 
5 Paalai (Desert)   
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Table. No 9. MODE OF ONSET 
 
 
 
 
Inference: 
  Out of 40 cases 87.5% of cases had Acute onset of symptoms and  
12.5% of cases had Chronic onset of symptoms. 
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S.No. Mode of onset Number of cases 
(Out of 40) 
Percentage (%) 
1 Acute 35 87.5 
2 Chronic 5 12.5 
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Table. No 10. CLINICAL FEATURES DURING ADMISSION 
 
S.No. Clinical features Number of cases 
(Out of 40) 
Percentage 
1 Itching 40 100 
2 Erythema 22 55 
3 Papules 40 100 
 
4 Vesicles 30 75 
5 Oozing 30 75 
6 Bleeding 13 32.5 
 
 
 
Inference: 
  Among 40 cases 100 % of the patients had Itching and Papules.  75% of 
the patients had Vesicles and Oozing, 55% of the patients had Erythema and 
32.5% of the patients had Bleeding 
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Table. No 11. TRIDOSHA REFERENCE 
 
DERANGEMENT OF  VATHAM 
 
 
 
 
Inference 
 According to Vatham, derangement of Viyaanan and Samaanan was  
100% , Abaanan was derangement of  45% of cases, Koorman and Kirukaran 
was  25% an derangement of  25% of cases. 
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S.No. Classification of Vatham Number of cases 
(Out of 40) 
Percentage (%) 
1 Piranan - - 
2 Abaanan 18 45 
3 Viyanan 40 100 
4 Uthanan - - 
5 Samaanan 40 100 
6 Naagan - - 
7 Koorman 10 25 
8 Kirukaran 10 25 
9 Devathathan - - 
10 Thananjeyan - - 
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DERANGEMENT OF  PITHAM 
 
S.No. Classification of Pitham Number of cases 
(Out of 40) 
Percentage (%) 
1 Anal pitham - - 
2 Ranjagam 40 100 
3 Sathagam 30 75 
4 Prasagam 40 100 
5 Alosagam - - 
 
 
 
Inference : 
 According to Pitham, derangement of Ranjagam and Prasagam was 
100% and Sathagam was derangement in 75% of cases. 
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DERANGEMENT OF  KABAM 
 
 
 
Inference: 
 Derangement of  Kabam, derangement of Kilethagam and Santhigam 
was 12.5%. 
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S.No. Classification of Kabam Number of cases 
(Out of 40) 
Percentage (%) 
1 Avalambagam - - 
2 Kilethagam 5 12.5 
3 Pothagam - - 
4 Tharpagam - - 
5 Santhigam 5 12.5 
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Table. No 12. EZHU UDARKATTUGAL REFERENCE 
 
 
 
Inference : 
 Saaram, Senneer, kozhuppu was affected in 100% of cases and Oon, 
Enbu was affected in 87.5% of cases. 
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S.No. Ezhu udarkattugal 
Number of cases 
(Out of 40) Percentage (%) 
1 Saaram 40 100 
2 Senneer 40 100 
3 Oon 35 87.5 
4 Kozhuppu 40 100 
5 Enbu 35 87.5 
6 Moolai - - 
7 Sukkilam/Suronitham - - 
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Table. No 13. ENVAGAI THERVUGAL  
S.No. Envagai thervugal 
Number of cases 
(Out of 40) 
Percentage 
1 Naa - - 
2 Niram 40 100 
3 Mozhi - - 
4 Vizhi  - - 
5 Sparisam  40 100 
6 Malam 18 45 
7 Moothiram - - 
8 Naadi - - 
         a.  Vatha pitham 22 55 
         b. Pitha vatham 14 35 
         c. Vatha kabam 4 10 
 
 
 
 
Inference: 
 In Naadi, Vaatha pitham was observed in 55% of cases,Vatha kabam 
was observed in 10% of cases, Pitha vatham was observed in 35% of cases,  
derangement of Niram and Sparisam were observed in 100% of cases, Malam 
erugal was observed in 45% of cases. 
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Table. No 14. NEERKURI , NEIKURI REFERENCE 
 
NEERKURI 
 
 
 
Inference: 
 Neerkuri was observed in 100% of cases. 
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S.No. Neerkuri 
Number of cases 
(Out of 40) 
Percentage 
1 Neerkuri 40 100 
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NEIKURI  
 
S.No. Neikuri 
Number of cases 
(Out of 40) 
Percentage 
1 Vatha neer  (Spreads like serpent) 36 90 
2. Pitha neer    (Spreads like ring) 2 5 
3. Kaba neer   (Spreads like pearl) 2 5 
 
 
 
Inference: 
 According to Neikuri, Vatha neer was observed in 90 % of cases, Pitha 
neer  and Kaba neer was observed in 5% of cases. 
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Table. No 15. OUT PATIENT RECORD 
S.No Op.No. Name Age /Sex No. of  days treated Remarks 
1. 46157 Sai Raju 12FC 21 days Good 
2. 51876 Paerumila 8FC 21 days Good 
3. 81471 Suriya narayanan 12MC 21 days Good 
4. 79420 Mukaesh 6MC 21 days Good 
5. 81479 Sanjay 7MC 21 days Mild 
6. 84486 Carolin 11FC 21 days Moderate 
7. 84453 Sathiya 12FC 21 days Good 
8. 101841 Gayathiri 12FC 21 days Moderate 
9. 96386 Sivakumar 10MC 21 days Good 
10. 99680 Siva 4MC 21 days Good 
11. 99858 Ashuika 5FC 21 days Mild 
12. 81231 Silvia jesi 8FC 21 days Good 
13. 79742 Shakthi sangari 7FC 21 days Good 
14. 100409 Sathish kumar 11MC 21 days Moderate 
15. 79700 Nithish kumar 8MC 21 days Good 
16. 65420 Madasamy 12MC 21 days Good 
17. 50282 Mujebu 3 ¼  MC 21 days Mild 
18. 65345 Agim 4MC 21 days Good 
19. 46379 suthish 12MC   21 days Moderate 
20. 79854 Lakshan 8MC 21 days Good 
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Table. No 16. INPATIENTS CASE SHEET REPORTS 
S.No IP No Name of patient Age/sex Duration 
of illness Signs and symptoms 
Admission 
date 
Discharge 
date 
No.of days 
Treated Result 
1. 2607 Shilviya 8FC 3 Months Itching all over the body, papules, vesicles 
oozing, bleeding present 18.10.2018 18.11.2018 18 Good 
2. 3031 Nithish 6MC 2 Weeks Itching, papules, vesicles, oozing  present in  both upper limbs and lower limbs 
10.12.2018 
 
31.02.2018 18 Good 
3. 3062 Joshpin 3FC 3 Weeks Itching, papules, vesicles, oozing  present in both legs 12.12.2018 31.12.2018 20 Good 
4. 3152 Paechiyammal 11FC 3 Months Itching, papules, vesicles, oozing, bleeding present in both upper limbs and lower limbs 26.12.2018 19.01.2019 19 Moderate 
5. 3153 Benisha 7FC 1 Week Itching, papules, vesicles, oozing, bleeding present in lower limbs, Pain in lower limbs 26.12.2018 19.01.2019 22 Good 
6. 3157 Keerthika 12FC 2 weeks 
Itching all over the body papules pain 
present in lower extremities mainly in knee 
joints  
26.12.2018 19.01.2019 21 Mild 
7. 3159 Nazaar 10MC 3 Months 
Itching all over the body papules present, 
Pain present in both knee joints and also in 
elbow joint 
26.12.2018 10.01.2019 16 Good 
8. 3158 Anuram 5MC 1 Week Itching all over the body, papules present   26.12.2018 19.01.2019 4 Moderate 
9. 3195 Sheriba 3FC 2 Years 
Itching, papules, vesicles, oozing present in 
both lower limbs, Pain present in both knee 
joints 
31.12.2018 19.01.2019 4 Good 
10. 53 Mahalakshmi 7FC 2 Weeks 
Itching all over the body, papules, vesicles, 
oozing present, Pain present in both knee 
joint 
12.01.2019 05.02.2019 15 Good 
11. 54 Chellakannu 10FC 3 Weeks Itching, papules, vesicles, oozing, bleeding present in both lower limbs 12.01.2019 03.02.2019 14 Good 
12. 89 Marideepika 12FC 2 Months 
Itching all over the body, papules, vesicles 
oozing present, Pain present in both knee 
joint 
19.01.2019 11.02.2019 14 Moderate 
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Table. No 16. INPATIENTS CASE SHEET REPORTS 
S.No IP No Name of patient Age/sex Duration 
of illness Signs and symptoms 
Admission 
date 
Discharge 
date 
No.of days 
Treated Result 
13. 97 Mahesh babu 12MC 1 Month Itching all over the body including scalp, 
papules, vesicles oozing present  20.01.2019 11.02.2019 13 Good 
14. 99 Raja 9MC 1 Week Itching all over the body, papules, vesicles, 
oozing present  20.01.2019 08.02.2019 8 Mild 
15. 100 Shakthi 7FC 1 Month Itching all over the  body and also in scalp, 
papules, vesicles, oozing, bleeding present  20.01.2019 08.02.2019 7  Good 
16. 243 Abinaya 4FC 2 Weeks Itching, papules, vesicles, oozing present in 
both lower limbs 04.02.2019 01.03.2019 7 Good 
17. 323 Srimathibala 8FC 2 Months Itching, papules, vesicles, oozing present in 
both upper and lower limb 11.02.2019 04.03.2019 13 Moderate 
18. 380 Afrose 12FC 1Month Itching all over the body, papules, vesicles, 
oozing present 16.02.2019 08.03.2019 12 Good 
19. 381 Subashini 3FC 1 Month Itching all over the body , papules, vesicles, 
oozing present, Pain present in both knee 
joint 
16.02.2019 08.03.2019 5 Good 
20. 383 Surya prakash 7MC 1Month Itching, papules, vesicle, oozing, bleeding 
present in both upper and lower limbs 16.02.2019 08.03.2019 5 Good 
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Table. No 17. LABORATORY INVESTIGATIONS 
BT – Before Treatment,   AT -  After Treatment, P – Polymorphs,  L – Lymphocytes, E-Eosionophils,   ESR – Erythrocyte 
Sedimentation Rate, Hb - Haemoglobin A- Albumin, S – Sugar, D – Deposits,N - Nil 
S.No. IP.No Name of the patient 
Age / 
Sex 
Haematological Investigation Urine Analysis Motion Analysis 
WBC Total 
Count cells /  
cu.mm 
WBC differential count ESR – mm/ Hr Hb gm% Before Treatment After Treatment 
Before 
Treatment 
After 
Treatment 
BT AT BT AT 
A S D A S D Ova Cyst Ova Cyst 
BT AT P% L% E% P% L% E% 
½ 
hr 1hr 
½ 
hr 1hr BT AT 
1 2607 Shilviya 8FC 9000 9200 62 30 8 64 30 6 5 10 4 8 11 11 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
2 3031 Nithish 6MC 9600 9800 54 44 2 54 45 1 7 14 6 12 9 11 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
3 3062 Joshpin 3FC 8200 9600 55 35 10 57 37 6 6 12 5 10 12.1 12.6 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
4 3152 Paechiyammal 11FC 7800 8600 47 44 9 48 44 8 5 10 4 8 12 12 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
5 3153 Benisha 7FC 10000 10050 54 39 7 55 40 5 7 14 4 8 9 10 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
6 3157 Keerthika 12FC 8600 8700 65 30 5 66 30 4 6 12 5 9 9.1 10.5 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
7 3159 Nazaar 10MC 8300 8400 59 36 5 60 35 5 8 16 6 15 10 10 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
8 3158 Anuram 5MC 11200 11400 66 28 6 66 39 5 6 12 5 10 11.2 11.4 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
9 3195 Sheriba 3FC 8800 9000 48 44 8 49 44 7 7 14 4 8 12.1 13 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
10 53 Mahalakshmi 7FC 9500 9600 60 32 8 60 34 6 6 12 4 8 9.9 10.4 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
11 54 Chellakannu 10FC 8300 8500 60 35 5 61 35 4 5 10 3 7 9 10 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
12 89 Marideepika 12FC 8700 9200 56 37 7 57 39 4 6 12 5 10 7.8 8.7 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
13 97 Mahesh babu 12MC 9650 9750 68 26 6 68 29 3 6 12 4 9 8.9 9 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
14 99 Raja 9MC 9400 9600 64 30 6 65 31 4 7 15 5 10 11.5 12 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
15 100 Shakthi 7FC 8300 8500 52 40 8 53 42 5 5 10 4 8 10.5 11.2 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
16 243 Abinaya 4FC 8800 9000 56 34 10 59 35 6 8 16 7 14 11 12 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
17 323 Srimathibala 8FC 9200 9500 60 26 14 60 30 10 9 18 5 10 9.2 10.5 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
18 380 Afrose 12FC 9800 9900 59 35 6 62 35 3 7 14 6 12 11.5 11.7 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
19 381 Subashini 3FC 7950 8050 68 26 6 68 28 4 8 16 7 14 9.5 10 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
20 383 Surya prakash 7MC 9750 9800 61 30 9 62 31 7 6 12 5 10 10 11.5 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
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Fig. No. 9 
IP. No. 3158   Name : Anuram  Age :  5/MC 
 
 
 
 
 
 
 
 
 
 
IP. No. 3157   Name : Keerthika  Age :  12/FC  
 
 
 
 
 
 
 
 
 
OP. No. 99680  Name : Siva   Age :  4/MC  
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Table. No 18. RESULTS AFTER TREATMENT 
 
  
 
  
 
Inference: 
 Out of 40 patients, 70% of cases showed Significant improvement, 20% 
of cases showed Moderate improvement and 10% of cases showed Mild 
improvement. 
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S.No. RESULTS 
Number of cases 
(Out of 40) 
Percentage 
(%) 
1. Good  28 70 
2. Moderate 8 20 
3. Mild 4 10 
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Table. No 19. RESULTS ACCORDING TO AGE CRITERIA AFTER 
TREATMENT 
S.N
o 
Age 
Good Relief Moderate Relief Mild Relief 
Number 
of Cases              
(Out of 
40 ) 
Percentage 
(%) 
Number 
of Cases              
( Out of 
40 ) 
Percentage 
(%) 
Number 
of Cases            
(Out of 
40 ) 
Percentage 
(%) 
1. 3 – 7 Years 15 37.5 5 12.5 2 5 
2. 7 – 12 years 11 27.5 4 10 3 7.5 
  
 
 
Inference: 
 Among 40 cases, the Good Relief percentage was highest in the age 
group of   3 – 7 years, the percentage was 37.5% and between the age group of 
7 – 12 years, the percentage was  27.5% 
  The Moderate Relief percentage was highest in the age group of 3 – 7 
years, the percentage was 12.5% and were as 10% between the age group of     
7 – 12.  
  The Mild Relief percentage was 7.5% highest percentage between the 
age group of 7 – 12 years and 5% present in 3-7 years of age. 
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10. DISCUSSION 
  Nowadays allergic diseases are widely prevalent in people from all the walks 
of life. This because of life style changing of the people and their dietetic patterns, 
also the atmosphere pollution with seasonal changes are determinating the 
immunoresponse of the individual to fight against the disease 
  Sattai Karappan is one of the commonest clinical entity encountered in 
Kuzhanthai Maruthuvam practice resembles in its clinical features with “Atopic 
Dermatitis” in Modern Medicine. 
Causative  Factors: 
  Siddha system of medicine describes that the causes of this disease are allergic 
food excessive intake of kambu, cholam, varagu, contactants, cosmetics, clothing and 
associated with allergic disorders. 
  In Modern Aspects, the cause are of hypersensitivity to a variety of contact of 
contact allergens (plants, clothing, medicaments), irritants (physical and Chemical) 
history of allergies, emotional factors and familial predisposition. 
 
With reference to age group 
 Patients suffered from Sattai karappan ranged between the age group 3-7 years 
(47.5%)   7-12 years (52.5%) my research study shows that the patients between the 
age group of 7-12 years (52.5%) were more affected. 
Incidence with sex reference 
 12 were male children and 28 were female children are taken for research 
studies. 
With reference to religion 
 Among 40 patients 92.5% patients are hindu, 2.5% patients are Christian and 
5% patients belongs to Muslim. 
With reference to socio-economic status 
 Among 40 patients 28(70%) patients belong to poor status, 7(17.5%) patients 
belongs to middle class and 5(12.5%) patients belong to rich class. 
Reference to etiology 
 Out of the 40 patients 
10 patients (25%) were affected by familial predisposition. 
30 patients (65%) were affected by others (diet, climate, immune dysfunction, 
psychological) and unknown. 
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With reference to diet 
 Out of 40 patients, 5 patients have vegetarian diet and 35 patient have mixed 
diet. 
With reference to paruva kalam 
 According to Paruvakaalam high incidence 35% of cases in Munpani Kaalam, 
27.5% of cases in Kaarkalam, 17.5% cases in Koothir Kaalam 12.5% Cases in 
Muthuvenil kaalam and 7.5 % cases in Pinpani kaalam 
With reference to distribution of lands 
 Out of 40 patients, 39 patients (97.5%) belongs to marutham nilam and 1 
patients (2.5%) belongs to neithal nilam. 
With reference to mode of onset 
 Out of the 40 patients 10 cases (25%) affected by acute infection and 30 cases 
(75%) affected by chronic infection. 
With reference to clinical features 
Itching present in 40 cases (100%) 
Papules present in 40 cases (100%) 
Oozing present in 28 cases (57.5%) 
Erythema present in 26 cases (65%) 
Oedema present in 12 cases (30%) 
Scaling present in 2 cases (5%) 
Vesicles present in 28 cases (57.5%) 
Pustules present in 1 cases (2.5%) 
Excriation present in 12 cases (30%) 
Crusting present in 12 cases (30%) 
Xerosis present in 10 cases (25%) 
Lichenification present in 8 cases (20%) 
Constipation present in 18 cases (45%) 
Sneezing present in 10 cases (25%) 
Tridosha reference 
 Among 40 patients, abanan (45%) constipation. Viyanan (100%) pain, itching, 
Samaanan (100%), Kirukaran (25%) sneezing, Koorman (25%) are affected in 
vatham. 
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 Among 40 patients Ranjagam (100%) (Raised ESR, Raised eosionphil count) 
and prasagam (100%) (colour change in skin), Sathagam (75%) are affected in 
pitham. 
 Among 40 patients, kilethagam (12.5%), Santhigam (12.5%) were affected in 
kabam. 
With reference to ezhu udal kattugal 
 Saaram was affected in all 100% of patients (tiredness, mental depression). 
 Senneer was affected in 100% of patients (raised ESR, raised eosinophil 
count) and oon was affected in 87.5% patients, kozhuppu was affected in all 100% of 
patients.  Enbu was affected in 87.5% if patients. 
With reference to Envagai thervugal 
 On examination of envagai thervugal.  Niram and sparisam were affected in 
all 40 patients (100%), Malam was affected in 18 patients (45%). 
With reference to Neerkuri, neikuri. 
 In neerkuri, the urine of all the 40 patients (100%) was straw coloured. 
 In neikuri, the urine of 34 patients (85%) resembled a pearl, urine of 4 patients 
(10%) spreads like snake and the remaining 2 patients (5%) spreads like ring. 
With reference to results after treatment 
 Out of 40 patients, 27 patients (67.5%) have good relief, 8 patients (12.5%) 
have moderate relief and remaining 5 patients (20%) have mild relief. 
Treatment 
 The trial medicine for the treatment of  Sattai karappan  were  “Karappan  
kudineer chooranam” administered orally and “Karappan Ennai” applied externally. 
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11. SUMMARY 
 The research study on Sattai Karappan is chosen with the patients who are 
suffering from this disease. 
 Various literatures having relevant reference to the disease, “Sattai Karappan” 
were collected from both siddha system as well as in modern system of medicine. 
 Twenty cases from both sexes of different age groups were selected and 
treated with “Karappan Kudineer Chooranam” as internally “Karappan Ennai” as 
externally in the out-patients and Inpatients ward of post graduate kuzhanthai 
maruthuvam Department. 
 The In-patient were treated 5 to 30 days depending upon the severity of illness 
and they were advised to attend the out-patient department for further follow up. 
 Routine laboratory investigations were done in the college and the prognosis 
of the patients was noted. 
 The clinical diagnosis of “Sattai karappan were done on the basis of siddha 
aspects. 
 The clinical study were conducted in 20 out-patients and 20 In-patients, 27 
had good relief (67.5%) 8 had moderate relief (20%) and 5 had mild relief (12.5%). 
 The efficacy of the trial medicine were studied by Biochemical, 
microbiological study and pharmacological analysis. 
 To rule out the toxicity, the trail medicine were studied by toxicology analysis. 
 The biochemical analysis reveals the presence of calcium, sulphate, chloride, 
tannic acid, unsaturated compound. reducing sugar, amino acid in the drug Karapan 
Kudineer Chooranam. 
 The toxicity study in “Karappan Kudineer Chooranam” and dermal toxicity of 
Karappan Ennai reveals that there is no acute toxicity effects in this drug. 
 The pharmacological analysis of the drug “Karappan Kudineer Chooranam” 
possesses significant activity on anti-inflammatory and anti-histamine action. 
 The microbiological analysis reveals resistant for pseudomonas aeruginosae 
and sensitive for staphylococcus aureus. 
 Thus the analysis ensure the efficacies of the trial medicines which were 
proved clinically. 
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12. CONCLUSION 
 
 The clinical study show that 70% of the patient were completely cured and 
also proved clinically, there was no recurrence of symptoms. 
 The trial medicines were very effective to patients and are free from adverse 
effects. 
 The drugs are not expensive and also easily available. 
 The trial medicines were very safe to the children. 
 Thus is conclude “Sattai Karappan” is controllable and curable disease with 
“Karappan Kudineer Chooranam” and Karappan Ennai along with good personal 
hygiene and diet. 
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CASE SHEET PROFORMA 
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “SATTAI KARAPPAN”                                  
-A PEDIATRIC DISORDER AND THE DRUG OF CHOICE IS  KARAPPAN 
KUDINEER CHOORANAM (INTERNAL),  KARAPPAN ENNAI (EXTERNAL) 
 
Form I-SCREENING & SELECTION PROFORMA 
S.I.No: ………….  OP/IP No: ……….  Name: ……………… 
Age: …………….  Gender: …………..Date of Enrollment: …………. 
Date of Completion :…………. Informant:…………. Reliability :  …………… 
INCLUSION  CRETERIA:     YES      NO   
 Age  : 3 to 12 years 
 Sex  : Both male and female children 
 Intense itching 
 Erythema 
 Papules 
 Papulovesicles 
 Crusted lesion all over the body 
 Ulceration 
 Exudation 
 Constipation 
EXCLUSION CRITERIA: 
 Children above 12 years 
 Scabies 
 Psoriasis 
 Secondary bacterial infection 
 Contact dermatitis 
 Seborric dermatitis 
 Furunculosis 
 Neurodermatitis 
Signature of Guide:              Signature of Principal Investigator: 
 
Signature of HOD:  
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “SATTAI KARAPPAN”                                  
-A PEDIATRIC DISORDER AND THE DRUG OF CHOICE IS  KARAPPAN 
KUDINEER CHOORANAM (INTERNAL),  KARAPPAN ENNAI (EXTERNAL) 
 
FORM IA – HISTORY PROFORMA ON ENROLLMENT 
 
Patient id: OP/IP NO. VISIT DATE (___/____/_____) 
NAME :  
AGE:  
Gender:   MALE           FEMALE  Date Of Birth :( ____/____/_____)   
Fathers/Mother/Guardian name :  
Fathers Occupation:  
Fathers Monthly income:  
Religion:  
Socioeconomic status:  
Patient informant :  
 
 
 
 
 
 
  
Postal Address  
 
Contact no: 
xv 
 
1. Complaints and duration  
 
2. Present illness  
History of past Illness 
History /Symptoms /Signs   Yes  No  if, Yes Details  
Any Similar Complaints      _____________ 
Bronchial Asthma       _____________ 
Dust Allergy        _____________ 
Hospitalization        _____________ 
Any Other         _____________ 
 
Family History       
Any hereditary familial Disease    Yes  No 
If yes, details………………………………………………………………………….. 
 
Immunization History  
Proper Immunization given   Yes  No …………………….. 
 
Food Habits:  
1. Veg   2. Non-Veg   3. Mixed  
 
General assessment                            Yes  No 
1. Picca 
2. Nail Biting 
3. Bowel Movements  
 
General Examination   Yes  No   
1. Pallor       
2. Jaundice        
3. Cyanosis         
4. Clubbing         
5. Pedal oedema        
6. Lymph adenopathy         
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
xvi 
 
Vital signs:- 
1. Pulse rate / mint 
2. Heart rate / mint 
3. Respiratory Rate / mint 
4. Temperature 
5. BP 
 
Anthropometry: 
 Height 
Weight 
Head Circumference 
Chest Circumference 
Mid Arm Circumference 
 
CLINICAL EXAMINATION: 
             Normal            Affected 
 Cardio Vascular system:        
 Gastro intestinal system:        
 Musculo skeletal system:        
 Central nervous system:        
 Endocrine system:  
 
CLINICAL EXAMINATION OF SKIN: 
1. Site: 
………………………………………………………………………………… 
 
………………………………………………………………………………..... 
2. Colour: Normal    Reddish      Black    Pallor    
3. Itching: No                     Mild                 Moderate            Severe                   
 
EXAMINATION OF NAILS: 
1. Pallor:  Present              Absent               
2. Koilonychia: Present              Absent               
 
  
  
  
  
  
    
   
  
  
xvii 
 
Nilam:  
 
            Kurinji  Mullai                Marutham        Neithal         Paalai 
KaalaIyalbu 
Kaarkalam  Koothirkaalam Munpanikaalam 
Pinpanikaalam Illavenikaalam Muthuvenrkaalam 
Yaakai 
 
Vatham  VathaPitham  VathaKabam 
 
Pitham   PithaVatham  PithaKabam 
 
Kabam   KabaVatham  KabaPitham 
UyirThathukkal 
Vatham 
  Normal Affected  Remarks  
Praanan 
Abaanan 
Uthaanan 
Viyaanan 
Samaanan 
Nagaan 
Koorman 
Kirugaran 
Devathathan 
Dhanajeyan 
 
Pitham 
     Normal  Affected  Remarks  
Analagam 
Ranjagam 
Saathagam 
Alosagam 
Prasagam 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
xviii 
 
 
Kabam 
     Normal   Affected  Remarks  
Avalambagam 
Kilethagam 
Pothagam 
Tharpagam 
Santhiga 
 
Udalthathukkal 
      Normal    Affected  Remarks  
Saaram 
Senneer 
Oon 
Kolupu 
Enbu 
Moolai 
Sukilam/Suronitham 
 
EnvagaiThervugal 
   Normal Affected  Remarks  
Naa 
Niram  
Mozhi  
Vizhi  
Malam 
Niram     
Nurai     
Elagal  
Erugal  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
  
  
  
xix 
 
Moothiram 
Neerkuri:  
Niram  Normal   Affected 
Edai  Normal   Affected 
Nurai  Normal   Affected 
Manam Normal   Affected 
 Enjai  Normal   Affected  
Neikuri: 
 Vatham 
 Pitham 
 Kabam 
 Others 
 
Naadi: 
ThaniNadi 
 Vadham  Pitham   Kabam 
 
ThonthaNadi 
 VathaPitham  Pithavatham PithaKabam Kabapitham 
 
Sparism 
Diagnosis__________________________________ 
Admitted to trial : 1. Yes   2. No. 
if yes, S.No:  1IP   2.OP 
 
Diagnosis 
DRUGS ISSUED:______________ 
Date :________________________ 
Station _______________________ 
Date :      
Signature of the Guide   Signature of Principal Investigator: 
 
Signature of the HOD  
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “SATTAI KARAPPAN”                                  
-A PEDIATRIC DISORDER AND THE DRUG OF CHOICE IS  KARAPPAN 
KUDINEER CHOORANAM (INTERNAL),  KARAPPAN ENNAI (EXTERNAL) 
 
FORM-IB:CASE SHEET PROFORMA-“SATTAI KARAPPAN” 
 
 
 
 
 
 
 
 
           
  Religion: 
       
       
       
 
 
 
 
 
 
 
     
  
I.P.No. : 
 
Bed. No. : 
 
Name of the Medical unit: 
 
Name : 
 
Age/Sex: 
 
Permanent Address: 
 
 
 
 
Temporary Address: 
PG-Pediatric Ward, Government Siddha 
Medical College & Hospital, 
Palayamkottai. 
Informant: 
 
Invesitgator: 
 
 
Nationality: 
 
Religion: 
 
Occupation(Parents): 
 
Income: 
 
Date of Admission: 
 
 
Date of  Discharge: 
 
 
Diagnosis: 
 
 
 
 
 
 
 
 
 
 
Medical Officer: 
xxi 
 
Complaints and duration : 
 
 
 
History of present illness : 
 
 
 
History of past illness : 
 
 
Personal History: 
 
 
Family History: 
 
Consanguinity    : 
 Ataxia     : 
 Blindness    : 
 CP     : 
 MR     : 
 Seizure    : 
 Movement disorder   : 
 Deafness    : 
  
Socio-Economic Status: 
 
Habits: 
 Bowel and micturation habit  : 
 Sleep     : 
 Enuresis    : 
 Thumb sucking   : 
 Nail biting    : 
 Pica     : 
xxii 
 
Diet History : 
 Appetite    : 
 Types of diet    : 
 
Antenatal History : 
 Medication    : 
 Infection (STARCH)   : 
 Irradiation    : 
 Toxaemia    : 
 Hemorrhage    :  
 Severe Anaemia   : 
 Eclampsia    : 
 H/o Decreased foetal Movements : 
 Maternal malnutrition   : 
 Maternal Diabetes Mellitus(DM) : 
 Maternal Hypertension  : 
 
Natal: 
 Breech presentation   : 
 Forceps / - C- Section   : 
 Home / Hospital   : 
 H/o prolonged labour   : 
 
Post Natal 
 Post partumHaemorrhage  : 
 Sepsis     : 
 
Neonatal History: 
 Birth Weight    : 
 Term / Pre term baby   : 
 Congenital malformations  : 
 Birth Asphyxia – APGAR – Score : 
 Neonatal convulsions   : 
 Kernicterus    : 
xxiii 
 
 Diarrhoea    : 
 Birth injury / Head injury / Activity of the child 
a) at birth   : 
b) after birth   : 
Time of cry after birth  : 
Resusscitation done or not  : 
(if done nature of resusscitation) 
Respiratory distress / cyanosis : 
Fever / altered sensorium  : 
Feeding after birth   : 
Lymphadenopathy   : 
 
Developmental History : 
 
 
Immunization History : 
 
 
General Examination 
Anthropometry: 
 Height    : 
Weight    : 
Head Circumference   : 
Chest Circumference   : 
Mid Arm Circumference  : 
 
 
1. Consciousness : 
2. Decubitus  : 
3. Anemia   : 
4. Jaundice   : 
5. Cyanosis   : 
6. Clubbing   : 
7. Pedal oedema  : 
xxiv 
 
8. Lymphadenopathy   : 
9. Nourishment  : 
10. Skin changes   : 
11. Edema   : 
12.JVP   : 
13.Pulse Rate   : 
14.Heart Rate   : 
15.Respiratory Rate  : 
16.Temperature  : 
17.Blood Pressure  : 
18.Spine   : 
19.Skin    : 
 
Systemic Examination 
Cardio Vascular System : 
Respiratory System  : 
Gastro Intestinal System : 
Genito Urinary System : 
Nervous System  : 
 Consciousness: 
 Temper Tantrum:  Sociable- Irritable - Playful 
 Memory  : 
 Orientation  : 
 Speech   : 
 Intelligence (I.Q) : 
 Handedness  : 
 
Cranial Nerve Examination: 
Motor System: 
 Power  : 
 Tone  : 
 Reflex  : 
 Grip  : 
 Gate  : 
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Sensory Examination: 
 Superficial Sensation: 
  Touch  : 
  Pain  : 
  Temperature : 
 Deep Sensation: 
  Position sense : 
  Joint sense : 
  Vibration sense: 
 Cortical Sensation: 
   
 
Cerebellar Signs: 
 
 
Autonomic System: 
 
Siddha Systems – Clinical Examination: 
Nilam 
Kurinchi  : 
Mullai   : 
Marutham  : 
Neithal   : 
Palai    : 
ParuvaKaalam 
Kaar   : 
Koothir  : 
Munpani  : 
Pinpani   : 
Elavenil  : 
Muthuvenil  : 
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Uyirthathukal: 
Vatham 
Praanan  : 
Abaanan : 
Uthaanan  : 
Viyaanan  : 
Samaanan : 
Naagan  : 
Koorman : 
Kirugaran  : 
Devathathan : 
Dhananjeyan  : 
 
Pitham 
Analam  : 
Ranjagam  : 
Sathagam  : 
Alosagam  : 
Prasagam  : 
 
Kabam 
Avalambagam  : 
Kilethagam   : 
Pothagam   : 
Tharpagam   : 
Santhigam   : 
UdalKattugal 
Saaram    : 
Senneer   : 
Oon     : 
Kozhuppu   : 
Enbu     : 
Moolai    : 
Sukkilam/Suronitham  : 
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EnvagaiThervugal 
Naadi    : 
Sparisam   : 
Naa    : 
Niram    : 
Mozhi    : 
Vizhi    : 
Malam    : 
Moothiram   : 
Neerkuri 
Niram    : 
Manam   : 
Nurai    : 
Edai    : 
Enjal    : 
 
Neikuri 
 
 
Malakuri 
Nirami   : 
Nurai    : 
Elagal   : 
Erugal   : 
 
 
Lab Investigations 
1. Blood 
TC  : 
DC : 
Hb  : 
ESR  : 
2. Urine 
Albumin  : 
xxviii 
 
Sugar   : 
Deposits  : 
3. Motion 
Ova   : 
Cyst  : 
Occult blood  : 
DIFFERNTIAL DIAGNOSIS  : 
PROGNOSIS    : 
MARUTHUVAMURAI   : 
ADVICE     : 
DAILY PROGRESS   : 
 
Date 
 
Symptoms Medicine 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “SATTAI KARAPPAN”                                  
-A PEDIATRIC DISORDER AND THE DRUG OF CHOICE IS  KARAPPAN 
KUDINEER CHOORANAM (INTERNAL),  KARAPPAN ENNAI (EXTERNAL) 
 
FORM - II&IIA  
CLINICAL ASSESMENT ON ENROLLMENT DURING AND AFTER TRIAL 
S.I.No: ………….        OP/IP No: …………  Name: ……………… 
Age: …………….  Gender:  …………..   Date of Enrollment: ………… 
Date of Completion :………….   Informant: …………. Reliability :  …………… 
SIDDHA SYSTEM OF EXAMINATION 
 I.ENVAGAI THERVU: [EIGHT-FOLD EXAMINATION] 
1.NAADI: [PULSE PERCEPTION] 
2.SPARISAM: [SENSITIVITY] 
 
3.NAA:[TONGUE]  
 
4.NIRAM: [COMPLEXION] 
 
 
 
5.MOZHI: [VOICE] 
 
 
 
6.VIZHI: [EYES] (Lower palpebral conjunctiva) 
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7.MALAM: [BOWEL HABITS / STOOLS] 
 
 1stDay 7th Day 14th Day 21st Day 
Colour Dark/Yellow/ 
Red/ Pale 
Dark/Yellow/ 
Red/ Pale 
Dark/Yellow/ 
Red/ Pale 
Dark/Yellow/ 
Red/ Pale 
Consistency Solid/ 
Semisolid/ 
Watery 
Solid/ 
Semisolid/ 
Watery 
Solid/ 
Semisolid/ 
Watery 
Solid/ 
Semisolid/ 
Watery 
Stool bulk Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Constipation Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Diarrhoea Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
 
8.MOOTHIRAM[URINE EXAMINATION]: 
 
NEERKURI 1stDay 7th Day 14th Day 21st Day 
Niram White/ White/ White/ White/ 
[Colour] Yellowish/ Yellowish/ Yellowish/ Yellowish/ 
 Straw Straw Straw Straw 
 coloured/ Coloured/ coloured/ coloured/ 
 Crystal Crystal Crystal Crystal 
 clear clear clear clear 
Manam[Odour] Present/ 
Absent 
Present/ Absent 
 
Present/ Absent 
 
Present/ Absent 
 
Nurai[Froth] Nil/Reduced/ 
Increased 
Nil/Reduced/ 
Increased 
Nil/Reduced/ 
Increased 
Nil/Reduced/ 
Increased 
Edai[Sp.gravity] Normal/ 
Increased/ 
Normal/ 
Increased/R 
Normal/ 
Increased/R 
Normal/ 
Increased/R 
Enjal[Deposits] Present/ 
Absent 
Present/ Absent Present/ Absent Present/ Absent 
Volume Normal/ 
Increased/ 
Normal/ 
Increased/R 
Normal/ 
Increased/R 
Normal/ 
Increased/R 
 
 
 
 
xxxi 
 
 
 
 
 
 
 
II.THEGI: [TYPE OF BODY CONSTITUTION] 
 
III.NILAM: [ LAND WHERE PATIENT LIVED MOST] 
 
Kurinji Mullai  Marutham NeithalPalai 
    (Hillyterrain)      (Forestrange)         (Plains)           (Coastalbelt)  (Aridregions) 
IV.KAALAM: 
Kaarkalam  -   Pinpanikalam   - 
Koothirkalam  -   Ilavenil  - 
Munpanikalam -   Muthuvenil  - 
V.MUKKUTRAM:[AFFECTION OF THREE HUMORS]  
A)VATHAM: 
 1st Day 7th  Day 14th Day 21st Day 
Praanan     
Abaanan     
Viyaanan     
Udhaanan     
Samanan     
Naagan(Higher intellectual 
function) 
    
Koorman(airway of yawning)     
Kirukaran(Air of 
salivation/nasal  secrection) 
    
Devathathan (Air of laziness)     
Dhananjeyan(this air that acts 
on death) 
    
 
NEIKURI 1st Day 7th  Day 14th Day 21st Day 
Serpentine fashion     
Annular/Ringed  fashion     
Pearl beaded fashion     
Mixed fashion     
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B.PITHAM: 
 1st Day 7th  Day 14th Day 21st Day 
Analpitham (Gastric 
juice) 
    
Ranjagam(Haemoglobin)     
Saathagam(Life energy)     
Praasagam (Bile)     
Aalosagam     
 
C.KABAM: 
  
 1st Day 7th  Day 14th Day 21st Day 
Avalambagam (Serum)     
Kilaethagam (saliva)     
Pothagam (lymph)     
Tharpagam(cerebrospinal 
fluid) 
    
Santhigam(synovialfluid)     
 
 
VI.SEVEN DHATHUS: (7 SOMATIC COMPONENTS) 
 1st Day 7th  Day 14th Day 21st Day 
Saaram [Chyme]     
Senneer [Blood]     
Oon [Muscle]     
Kozhuppu [Fat]     
Enbu [Bones]     
Moolai [Bonemarrow]     
Sronitham[Genital  discharges]     
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 1.SYSTEMIC EXAMINATION: 
 1st Day 7th  Day 14th Day 21st Day 
1)Gastrointestinal  System     
2) Respiratory System     
3)Cardiovascular  System     
4)Central Nervous System     
5)Urogenital System     
 
Anthropometry: 
 Height    : 
Weight    : 
Head Circumference   : 
Chest Circumference   : 
Mid Arm Circumference  : 
 
 
2. GENERAL EXAMINATION: 
 
 
 1st 
Day 
3th  
Day 
6th 
Day 
9th 
Day 
12th 
Day 
15th 
Day 
18th 
Day 
21st 
Day 
Height (cms)         
Weight (kg)         
Temperature (F0)         
Pulse rate (per min)         
Heart rate (per min)         
Respiratory rate(per         
Blood pressure         
Anaemia         
Jaundice         
Cyanosis         
Lymph adenopathy         
Pedal edema         
Clubbing         
Jugular vein pulsation         
xxxiv 
 
 
3.CLINICAL SYMPTOMS: 
 
COMPLAINTS 1stDay 7th Day 14th Day 21st Day 
Intense Itching 
    
Pruritis 
    
Papules 
    
Erythema 
    
Papulo vesicles 
    
Ulceration 
    
Constipation 
    
Oozing 
    
Bleeding 
    
 
 
Date: 
 
Station: 
 
Signature of the Investigator: 
 
Signature of the Guide : 
 
 
    
        Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “SATTAI KARAPPAN”                                  
-A PEDIATRIC DISORDER AND THE DRUG OF CHOICE IS  KARAPPAN 
KUDINEER CHOORANAM (INTERNAL),  KARAPPAN ENNAI (EXTERNAL) 
 
S.I.No: ………….  OP/IP No: …………  Name: ……………… 
Age: …………….  Gender: …………..Date of Enrollment: …………. 
Date of Completion :…………. Informant:…………. Reliability :  …………… 
 
FORM III – LABORATORY INVESTIGATION 
 
Routine blood investigations Normal 
values 
Before 
TMT date: 
After TMT 
date: 
Hb (gms%)    11.5- 14.5   
T.RBC (milli/cu.mm) 4-4.9   
ESR(mm) ½ hr. 0-4   
1hr. 0-13   
T.RBC (milli/cu.mm) 5000-14500   
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 28-48   
Monocytes 3-6   
Eosinophils 0-3   
Basophils 0-1   
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Urine Investigation Before TMT  
Date : 
After TMT  
Date : 
Albumin   
Sugar   
Deposits   
 
 
Stools Investigation Before TMT  
Date : 
After TMT  
Date : 
OVA   
Cyst   
Occult blood   
 
 
 
Date : 
 
 
 
Signature of Guide:    Signature of Principal Investigator:
  
 
 
 
Signature of HOD:  
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GOVT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI 
PG. DEPT. OF KUZHANTHAI MARUTHUVAM 
 
       CONSENT FORM 
 
An open clinical study to evaluate the safety and efficacy of Siddha sasthric 
formulation“KARAPPAN KUDINEER CHOORANAM (Internally) & 
KARAPPAN ENNAI (Externally)” for the management “SATTAI KARAPPAN” 
 
CERTIFICATE BY INVESTIGATOR 
 
I certify that I have disclosed all the details about the study in the terms 
readily understood by the parent. 
Date ……………….      Signature………….. 
place ……………….     Name ……………… 
 
CONSENT OF INFORMANT 
I have been informed to my satisfaction, by the attending physician, the 
purpose of the clinical trial, and the nature of drug treatment and follow-up including 
the laboratory investigations to be performed to monitor and safeguardmy Son / 
Daughter body functions. 
I am aware of my right to opt out of the trial at any time during the 
courseofthe trial without having to give the reasons for doing so. 
I am, exercising my free power of choice; hereby give my consent to be 
included as a subject in the clinical trial of “KARAPPAN KUDINEER 
CHOORANAM (Internally) & KARAPPAN ENNAI (Externally)”for the 
treatment of “SATTAI KARAPPAN” 
Informant Signature:………. 
Date:        Informant Name: …………. 
Place:        Patient Name:………………. 
Signature of Witness     Relationship:………………… 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “SATTAI KARAPPAN”                                  
-A PEDIATRIC DISORDER AND THE DRUG OF CHOICE IS  KARAPPAN 
KUDINEER CHOORANAM (INTERNAL),  KARAPPAN ENNAI (EXTERNAL) 
 
S.I.No: ………….        OP/IP No: …………  Name: ……………… 
Age: …………….  Gender:  …………..   Date of Enrollment: …………. 
Date of Completion :…………. Informant: …………. Reliability :  …………… 
 
FORM IVB – WITHDRAWAL 
 
Date of Trial commencement  : 
Date of withdrawal from trial  : 
Reason (s) for withdrawal   : Yes /No 
Long absence at reporting   : Yes /No 
Irregular treatment    : Yes /No 
Shift of locality    : Yes /No 
Complication adverse reactions if any: Yes /No 
Exacerbation of symptoms   : Yes /No 
Pt. not willing to continue  : Yes /No 
Date : 
 
 
Signature of Guide:    Signature of Principal Investigator:
  
 
 
Signature of HOD:  
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FORM IV-C – PATIENT INFORMATION SHEET 
Name of the principal investigator: 
……………………………………………………. 
Name of the institution  :  GOVERNMENT SIDDHA MEDICAL  
         COLLEGE&HOSPITAL, 
 Palayamkottai 
Information sheet for patients participating in the open clinical, trial  
 
1, _____________________________________ Studying as PG Scholar at  
GOVERNMENT SIDDHA MEDICAL COLLEGE&HOSPITAL, 
PALAYAMKOTTAI  is doing a trail on the study “SATTAI KARAPPAN”. It  is a 
most common  disease in children. In this regard, I am in a need to ask you few 
questions. I will maintain confidentially of your comments and data obtained. There 
will be no risk of disclosing your identity and no physical, psychological or 
professional risk is involved by taking part in this study. Taking part in this study is 
voluntary. No compensation will be paid to you for taking part in this study.  
You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, 
taking part in the study may be of benefit to the community, as it may help us to 
understand the problem of defaulters and potential solutions.  
If you agree your child to be a participate in this study, he/she will be included 
in the study primarily by signing the concern form and then you will be given the 
internal medicine “KARAPPAN KUDINEER CHOORANAM (INTERNAL),  
KARAPPAN ENNAI (EXTERNAL) for 21 days 
 
Date : 
 
 
Signature of Guide:              Signature of Principal Investigator: 
 
 
Signature of HOD:  
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “SATTAI KARAPPAN”                                  
-A PEDIATRIC DISORDER AND THE DRUG OF CHOICE IS  KARAPPAN 
KUDINEER CHOORANAM (INTERNAL),  KARAPPAN ENNAI (EXTERNAL) 
 
FORM IVD- DIETARY ADVICE FORM 
 
S.I.No: ………….    OP/IP No: …………  Name: ……………… 
Age: ……………. Gender:  …………..   Date of Enrollment: …… 
Date of Completion :……… Informant: …………. Reliability :  …………… 
 
The following diet to be taken: The following food should be avoided 
• Drink adequatewater 
• Green leafy vegetables 
• Banana 
• Potato 
• Green onion 
• Buckwheat 
• Ricemilk 
 
• Brinjal 
• Brocolli 
• Cabbage 
• Bitterguard 
• Corn 
• Maize 
• Fish 
• Non-Veg foods 
 
Date: 
Station: 
 
Signature of the Investigator: 
 
Signature of the Guide : 
    
        Signature of the HOD 
1. Patient /Consumer Identification (Please complete or tick boxes below as 
appropriate) 
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Form – IVE 
NATIONAL PHARMACOVIGILANCE PROGRAMME FOR 
SIDDHA DRUGS 
Reporting Form For Suspected Adverse Reactions to Siddha Drugs 
 
Please Note: i. All Consumers/Patients and reporters information will remain  
          confidential.  
  ii. It is requested to report all suspected reactions to the concerned,  
                            even if it does not have complete data, as soon as possible.  
 
Peripheral centrecode :      State : 
 
Name  
 
 
Father Name  
 
Patient record no 
Ethnicity  
 
Occupation  
Address 
 
Village/Town 
Post/Via 
District /State 
Date of Birth/Age 
Sex:      Male /Female 
Weight: 
Degam: 
 
2. Description of the suspected adverse reactions please complete boxes below 
Date and time of initial 
observation  
 
 
 Season: 
xliii 
 
Description of reaction  
 
 
 Geographical area: 
3. List of all medicines/Formulations including drugs of other systems used by 
the patient during the reporting period:  
Medicine 
Daily 
dose 
Route of 
administration  
Vehicle – 
Adjuvant 
Date 
Diagnosis for which 
medicine taken Starting Stopped 
Siddha  
 
 
     
Any other 
system of 
medicines  
 
 
     
 
4. Brief details of the Siddha Medicine which seems to be toxic : 
1) 
Details Drug  
a) Name of the Medicine   
b) Manufacturing unit and 
batch no. and date 
 
c) Expiry date  
xliv 
 
d) Purchased and 
obtained from 
 
e) Composition of the 
formulation / part of 
the drug used 
 
 
2) Dietary restrictions if any 
3) Whether the drug is consumed under institutionally qualified medical 
     supervision or used as self medication 
4) Any other relevant information  
5. Treatment provided for adverse reaction: 
 
6. The result of the adverse reaction /side effect / untoward effects ( Please 
complete the boxes below )  
Recovered Not 
recovered: 
 
Unknown Fatal If fatal 
Date of death: 
Severe Yes /No Reaction abated after drug stopped or dose reduced 
 
Reaction reappeared after re introduction : 
 
Was the patient admitted to hospital? If 
yes, give name and address of hospital  
 
 
7. Any laboratory investigation done to evaluate other possibilities? If yes 
specify: 
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8. Whether the patient is suffering with any chronic disorders? 
 
Hepatic    Renal  Cardiac Diabetes Malnutrition  
Any Others  
 
9. H/O previous allergies /Drug reactions: 
 
10. Other illness (please describe): 
 
Type (please tick):Nurse/Doctor/Pharmacist/Health 
worker/Patient/Attendant/Manufacturer/Distribution /Supplier /Any other    
(please Specify) 
 
Name : 
 
Address: 
 
Telephone /E-mail if any: 
 
 
 
 
Signature of the reporter      Date : 
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Please send the completed from to  
 
From 
 
Government Siddha Medical 
College &Hospital, 
Palayamkottai, Post Graduate 
Department of Kuzhanthai 
Maruthuvam 
 
 
This Filled- in ADR report may be send within one month of observation / 
occurrence of ADR 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date : 
 
Station: 
 
Signature of Investigator: 
 
Signature of Guide:     Signature of HOD  
 
To, 
 The co-ordinator, 
Pharmacovigilance Department 
Govt., Siddha Medical College and 
Hospital, 
Palayamkottai, 
Who can report?  
 Any health care professionals like Siddha Doctors 
/Nurses /Siddha Pharmacists /Patients Etc.,   
What to report? 
 All reactions, Drug interactions 
Confidentiality  
 The patient’s identify will be held in strict confidence 
and protected to the fullest extent 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “SATTAI KARAPPAN”                                  
-A PEDIATRIC DISORDER AND THE DRUG OF CHOICE IS  KARAPPAN 
KUDINEER CHOORANAM (INTERNAL),  KARAPPAN ENNAI (EXTERNAL) 
 
Form IVF -ADMISSION – DISCHARGE SHEET 
Name of the medical unit  :    Nationality  : 
I.P.No     :     Religion  : 
Bed No    :    Informant  : 
Name     :    Date of Admission : 
Age/Sex    :    Date of Discharge : 
Occupation(parents)   :    No. of days treated  : 
Income(parents)   :    Diagnosis  : 
S.No Clinical Features 
During 
admission 
During 
discharge 
1 Itching   
2 Erythema   
3 Papules   
4 Pruritis   
5 Vesicles   
6 Crusted lesion   
7 Oozing   
8 Bleeding   
Place: 
Date:            
           
      Signature of the Medical Officer 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “SATTAI KARAPPAN”                                  
-A PEDIATRIC DISORDER AND THE DRUG OF CHOICE IS  KARAPPAN 
KUDINEER CHOORANAM (INTERNAL),  KARAPPAN ENNAI (EXTERNAL) 
 
FORM V-DRUG COMPLIANCE  
 
S.I.No: ………….  OP/IP No: ………… Name: ……………… 
Age: …………….  Gender: …………..  Date of Enrollment: …………. 
Date of Completion :…………. Informant:………..   Reliability :  …………… 
 
NAME OF THE DRUG   : KARAPPAN KUDINEER CHOORANAM (Int.) 
        KARAPPAN ENNAI  (Ext.) 
ADMINISTRATION &ADJUVANT : PER ORAL  
DOSE & DURATION    :  3 – 7  Years  -  30 ml for 21 days  
         7 – 12 Years  - 60ml for 21 days 
NO OF DRUG PACKS GIVEN   : ________________ 
NO OF DRUG PACKS  RETURNED : ________________ 
DAY 
DATE OF DRUG 
INTAKE 
MORNING EVENING 
DAY 1    
DAY 2    
DAY 3    
DAY 4    
DAY 5    
DAY 6    
DAY 7    
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DAY 8    
DAY 9    
DAY 10    
DAY 11    
DAY 12    
DAY 13    
DAY14    
DAY 15    
DAY 16    
DAY 17    
DAY 18    
DAY 19    
DAY 20    
DAY 21    
 
Date :                                                       Signature of Principal Investigator:  
 
Signature of the Guide: 
 
 
Signature of  HOD :  
